New allergens

Abstract

The present invention relates to the field of allergens, and more particularly to a novel isolated allergen from Cupressaceae species that has been shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous to Pru p7 in peach, and the protein belongs to the gibberellin-regulated protein (GRP) family. The novel allergen also shares high sequence homology with other species in the Cupressaceae family, thus providing additional novel allergens for two other species in the Cupressaceae family. The novel allergen finds use in the in vitro diagnosis, treatment, and / or prevention of type 1 Cupressaceae pollen allergy and Cupressaceae pollen-related food allergy.

Description

[Technical field]

[0001] The present invention relates to the field of allergy. More particularly, it relates to the identification of novel allergens from pollen of species belonging to the Cupressaceae family, and to the diagnosis and treatment of allergies to such pollen and especially related food allergies. [Background technology]

[0002] Approximately 20% of the population in industrialized countries become hypersensitive (allergic) upon exposure to antigens from various environmental biological substances or foods. Antigens that induce immediate and / or delayed hypersensitivity are mainly proteins or glycoproteins, called allergens [1], and are found in various sources, such as pollen, dust mites, animal dander, insect venom, and foods of plant or animal origin. The basic immunological mechanism of allergic diseases is the formation of allergen-specific immunoglobulin E (IgE) antibodies against such allergens, commonly referred to as sensitization. IgE antibodies bind to basophils, mast cells, and dendritic cells through a specific high-affinity IgE receptor, FcεRI. Upon exposure to allergens, allergen-specific IgE antibodies on the cell surface are cross-linked through the recognition of at least two different epitopes on each allergen molecule, leading to the release of inflammatory mediators such as histamine and leukotrienes from these cells. This results in tissue inflammation and the physiological symptoms of allergy [2].

[0003] In clinical practice, the diagnosis of allergy by physicians is usually based on a convincing clinical history of hypersensitivity to an allergen combined with evidence of sensitization to the same allergen. Diagnostic testing procedures for allergen sensitization can utilize either in vitro immunoassays to detect allergen-specific IgE antibodies in a patient's blood sample, or skin prick tests (SPTs) performed by topical application of an allergen extract to the patient's skin [3]. In both modalities, allergen reagents containing protein extracts from the allergen source are traditionally used. Although such tests may have high sensitivity and therefore high negative predictive value, sensitization to components in the natural allergen extract does not necessarily mean that clinical symptoms of allergy will occur. Such dissociation between detectable sensitization and clinical allergy is due, in part, to the unequal significance of different allergen proteins present in the natural extract. The fact that sensitization to certain proteins in the allergen source is more closely associated with clinical disease than others has paved the way towards the development of diagnostic tests with improved clinical utility by utilizing such specific proteins in pure form in diagnostic tests. In vitro diagnostic tests for IgE antibodies to individual allergen proteins are often called component-resolved diagnostics (CRD) [4].

[0004] It is now widely recognized that CRDs have several distinct advantages compared to conventional IgE assays using allergen extracts. One important feature of CRDs is their ability to distinguish between primary sensitization to an allergen source and sensitization due to cross-reactivity, the former being associated with more severe symptoms and the latter with milder symptoms or clinical tolerance. In food allergies, primary sensitization is usually directed to abundant and often stable proteins. As a consequence, accidental ingestion of even small amounts of the food in question will result in exposure to substantial amounts of such food proteins, resulting in a high risk of severe reactions in sensitized individuals. In contrast, food proteins that are homologous and cross-reactive with pollen allergens are usually present in small amounts and therefore rarely cause severe symptoms [5, 6]. Analysis of IgE antibodies against relevant food allergen components has been shown to significantly increase diagnostic value and clinical utility, as exemplified by allergies to wheat, peanuts, hazelnuts and cashew nuts [7–13]. By using the CRD, patients at high risk of severe and potentially life-threatening allergic reactions can be identified and instructed to strictly avoid food exposure and to always carry an epinephrine auto-injector for emergency treatment, while patients who are not at risk of such severe reactions can benefit from relief from unwarranted anxiety and improved quality of life.Similarly, in respiratory allergies, the ability of the CRD to distinguish between primary and cross-reactive sensitization facilitates the optimal selection of allergen immunotherapy treatment (AIT) targeted at the true cause of allergic symptoms rather than the less important cross-reactive sensitization

[14] .

[0005] Another application of purified natural or recombinant allergen components is their use as spiking reagents to counteract imbalances or deficiencies of the corresponding proteins in natural allergen extracts. This may be particularly important in miniaturized or non-laboratory immunoassays, such as allergen microarrays or clinic-based tests, where less favorable assay conditions, reduced ability of antibody-binding allergen reagents, and combinations of natural allergen extracts with limited potency may cause insufficient diagnostic sensitivity.

[0006] In 2016, the European Academy of Allergology (EAACI) published the "EAACI Molecular Allergology - User Guide" [1]. This was a milestone in recognizing the importance of testing allergy patients with allergen components for a more reliable diagnosis. By using this guide, allergists and other health professionals can better understand the level of cross-reactivity and risk associated with specific sensitization patterns, thereby providing a more appropriate management of their patients, including appropriate allergen avoidance strategies.

[0007] The most common treatments for allergies are pharmacological (e.g., antihistamines), which act to temporarily relieve symptoms but are not curative. Long-term and curative treatment of allergies can be achieved with allergen immunotherapy (AIT), which causes immunological desensitization of the patient. Treatment involves the administration, either subcutaneously or sublingually, of gradually increasing doses of an extract of the causative allergen from a very low level to a maintenance dose 100-1000 times higher. This controlled and gradually increasing allergen exposure causes a specific activation of a protective immune response against the allergen protein, sometimes also referred to as reeducation of the immune system. A possible further development of established forms of immunotherapy is the use of one or several purified allergen proteins instead of the natural allergen extracts. Trials of such immunotherapy have been successfully carried out for grass [15, 16] and birch

[17] pollen allergies and have also been proposed for the treatment of allergies to pet animals [4, 18].

[0008] Although the disease-modifying mechanisms of AIT are not fully understood, it is well known that it induces an allergen-specific IgG response, mainly consisting of the IgG4 subclass. These IgG antibodies may modulate the effects of IgE antibodies directly by blocking allergens or indirectly by acting through Fc receptors [19-21]. Since IgG antibody responses are thought to be part of the mechanism of successful immunotherapy [20, 21], the analysis of allergen-specific IgG may be a way to monitor the relevant immunological effects of the treatment. In conclusion, the measurement of allergen-specific IgG levels may reflect natural or induced tolerance to allergens through environmental exposure or immunotherapy treatment and, in combination with IgE measurements, may increase the clinical relevance of diagnostic tests in allergy.

[0009] Pollen allergens are the main cause of respiratory allergies in industrialized countries, and hay fever has been steadily increasing during the past decades, possibly as a result of climate change.

[22] Hay fever presents with various symptoms, such as seasonal rhinitis, conjunctivitis, and asthma. Pollen grains are released from flowers of grasses, weeds, and trees, and are dispersed either by wind or insects. Most allergenic pollen from trees is windborne and produced by species belonging to the orders Fagales, Lamiales, Proteales, and Pinales. The Pinales are gymnosperms and are characterized by having separate male and female flowers. Allergy-related Pinales species mainly belong to the Cupressaceae family and are found mainly in relatively warm climates.

[23] In the Mediterranean region, Cupressus sempervirens (Mediterranean or Italian cypress) is an important cause of winter hay fever, and the prevalence of sensitization to cypress pollen has increased dramatically in the past decades. In certain regions, sensitization rates can reach as high as 42% among atopic individuals [24, 25]. Mediterranean cypress is closely related to Arizona cypress (Cupressus arizonica) and somewhat more distantly related to mountain fern (Juniperus ashei, synonym J. sabinoides), Japanese cypress (Chamaecyparis obtusa), and Japanese fern (Cryptomeria japonica), found in North America and Japan, respectively. The major allergens of these species, Cup s 1, Cup a 1, Jun a 1, Cha o 1, and Cry j 1, each sensitize more than 90% of Cupressaceae pollen-allergic patients. All these allergens are glycoproteins, have molecular weights of 40–50 kDa, and belong to the pectate lyase protein family. The allergens are highly cross-reactive and share 70%–95% sequence identity [26, 27]. Group 2 allergens (Cup s 2, Cup a 2, Jun a 2, Cha o 2, and Cry j 2) belong to the polygalacturonase family and show 71%–97% sequence identity. Sensitization rates can be as high as 80% among cypress pollen allergic patients, and therefore it can also be considered a major allergen

[24] .Cupressaceae pollen allergens in groups 3 and 4, which belong to the thaumatin-like protein family and the polcalcin protein family, respectively, have been described as minor allergens.[27, 28] Beyond these four groups, about 15 other allergenic proteins have been reported in Cupressaceae pollen.

[0010] Sensitization to pollen is often associated with allergies to different plant foods due to cross-reactivity between homologous pollen and food proteins. Such cross-reactivity occurs as a result of structural similarities between homologous proteins present in pollen and plant-derived foods. The higher the level of amino acid sequence identity and three-dimensional structural similarity between such pairs of related proteins, the higher the probability and strength of cross-reactivity. Extensive cross-reactivity can be expected between proteins with 60% or more sequence identity to each other, but can also occur between less related proteins

[29] .

[0011] Pollen-related food allergies are thought to be driven primarily or entirely by pollen sensitization. This is usually referred to as oral allergy syndrome (OAS) because it causes oral symptoms. The most well-known and widespread example of pollen-related food allergy is caused by birch pollen and involves the so-called PR-10 protein Bet v 1 and homologous proteins in various fruits and vegetables

[30] . Another example is profilin-mediated food allergy, which can be driven by any pollen sensitization, which is less frequent and can cause allergies to foods such as melons, bananas, and other fruits [31, 32].

[0012] In yet another example, several patient cases showing an association between cupressaceae pollen sensitization and peach allergy were reported

[33] . In that study, a 45 kDa peach allergen was identified as a possible cause of cross-reactivity by immunoblot inhibition experiments. Recently, a novel peach allergen, designated Pru p 7 or peamaclein, was reported as the major allergen in peach-allergic patients in southern Italy

[34] . Pru p 7 is a 7 kDa cysteine-rich protein belonging to the gibberellin-regulated protein (GRP) family that has also been reported as an important cause of fruit allergy in Japan

[35] . In southern France, a significant association has been observed between severe peach allergy, characterized by Pru p 7 sensitization, and cupressaceae pollen allergy

[36] . By performing inhibition experiments, cypress pollen extract was found to outcompete IgE binding with Pru p 7, indicating the presence of a protein in cypress pollen that cross-reacts with Pru p 7. A 14 kDa protein designated BP14 from cypress pollen has been reported to contain a 13 amino acid residue peptide with sequence homology to another member of the GRP family, the potato protein snakin-1

[37] . This sequence stretch contains a highly conserved GRP segment that is identical in GRPs from over 40 plant species, as evidenced by a Blast search using the 13 residue BP14 sequence, but does not contain other available sequences from Cupressaceae species. Thus, the reported BP14 peptide does not contain sequence information characteristic and distinguishing Cupressaceae pollen GRPs, and therefore does not provide guidance toward specific features of such proteins. So far, a Cupressaceae pollen protein corresponding to Pru p 7 has not been identified and characterized.

[0013] Thus, there remains a need in the art to identify additional cypress pollen allergens that can be used in the diagnosis, prognosis, treatment and / or prevention of type 1 allergy, particularly allergens that show cross-reactivity with food proteins and that can induce sensitization and cause food allergic reactions. Summary of the Invention

[0014] The above needs are now met or at least alleviated by the identification and provision of a newly isolated 7 kDa allergen of Cupressaceae pollen (also referred to herein as Cup s GRP). The allergen is a 7 kDa basic cysteine-rich protein that is homologous to Pru p 7 in peach and belongs to the gibberellin-regulated protein (GRP) family, and has been shown to be likely to be the primary sensitizer of severe peach allergy mediated by Pru p 7. The discovery of such an allergen addresses a great need in the field of type 1 allergy diagnostics and the identification of Cupressaceae pollen-allergic individuals at risk of developing severe allergies to fruits and potentially other plant foods.

[0015] The allergen Cup s GRP identified herein shares high sequence homology with the corresponding pollen protein of other species from Cupressaceae family.Therefore, this specification also describes the identification of allergens containing Cup s GRP in three species from Cupressaceae family.The allergens identified from Cupressus sempervirens, Cryptomeria japonica, and Juniperus ashei are referred to herein as Cup s GRP, Cry j GRP, and Jun a GRP, respectively.The three pollen GRP allergens are also referred to as Cup s 7, Jun a 7, and Cry j 7.

[0016] Also presented herein are two protein isoforms of Cup s GRP, designated Cup s GRPa and Cup s GRPb, respectively.

[0017] Thus, in a first aspect herein, there is provided an isolated allergen protein (i.e. an allergen(s) identified herein), which comprises an amino acid sequence according to SEQ ID NO: 4 (i.e. Cup s GRPa), or a functionally equivalent protein fragment or variant thereof having at least 85% sequence identity with SEQ ID NO: 4. Also provided herein is an isolated allergen protein or a functionally equivalent protein fragment or variant thereof having at least 90%, such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 4.

[0018] Also provided herein is an isolated allergen protein comprising or consisting of an amino acid sequence according to any one of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:8 (i.e. CupsGRPa, CupsGRPb, JunaGRP and CryjGRP, respectively). Also provided herein is an isolated allergen protein or a functionally equivalent protein fragment or variant thereof having at least 90%, such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any one of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:8, respectively.

[0019] In a further aspect, an isolated nucleic acid molecule is provided that encodes each of the isolated proteins set forth herein, which is represented by a sequence according to SEQ ID NO: 10, which provides a degenerate DNA sequence of pollen GRP, including synonymous codons and variants according to the IUPAC ambiguity code.

[0020] In a further aspect, there is provided an expression vector (also referred to herein simply as a vector) comprising an isolated nucleic acid molecule comprising an isolated nucleic acid sequence disclosed elsewhere herein.

[0021] In yet another aspect, there is provided an isolated host cell comprising an expression vector as described herein, the host cell being used to express a protein of interest encoded by the expression vector.

[0022] In yet another aspect, there is provided a method for producing an allergen composition comprising the step of adding an isolated protein, or fragment or variant thereof, as described herein, to a composition comprising an allergen extract and / or at least one purified allergen component.

[0023] In yet another aspect there is provided an allergen composition obtainable by the method for producing an allergen composition described herein, said allergen composition comprising an isolated protein, or a fragment or variant thereof, as further defined elsewhere herein.

[0024] Also provided are allergen compositions comprising an isolated protein as described herein, or a fragment or variant thereof, and an allergen extract and / or at least one purified allergen component.

[0025] In yet another aspect, there is provided a use of the isolated protein disclosed herein, or a fragment or variant thereof, for the in vitro diagnosis or assessment of type 1 allergy.

[0026] In yet another aspect, provided herein is a method for the in vitro diagnosis or assessment of type 1 allergy, comprising the steps of contacting an immunoglobulin-containing body fluid sample from a subject suspected of having type 1 allergy with an isolated allergen protein, or a fragment or variant thereof as described herein, and determining the presence in the sample of antibodies, such as IgE antibodies, that specifically bind to the protein, fragment or variant, or a functionally equivalent fragment thereof, wherein the presence in the sample of antibodies, or functionally equivalent fragments thereof, that specifically bind to the protein, fragment or variant, is indicative with respect to type 1 allergy in the subject.

[0027] In yet another aspect there is provided a kit-of-parts comprising an isolated allergen protein, or fragment or variant as described herein, either soluble or immobilized on a solid support, said kit optionally further comprising detection reagents and / or instructions for use.

[0028] In another aspect, there is provided an isolated protein as disclosed herein, or a fragment or variant thereof, for use in the treatment or prevention of type 1 allergy.

[0029] In yet another aspect, there is provided a pharmaceutical composition comprising an isolated allergen protein disclosed herein, or a fragment or variant thereof, and a pharma- ceutically acceptable carrier and / or excipient.

[0030] In yet another aspect, there is provided a method for the treatment or prevention of type 1 allergy, comprising administering a pharma- ceutical effective amount of an isolated allergen protein, or a fragment or variant thereof, or an allergen composition, or a pharmaceutical composition, as provided herein, to a subject in need thereof. [Brief description of the drawings]

[0031] [Figure 1]Figure 2 shows the first purification step of native Pru p 7 by cation exchange chromatography. The absorbance at 280 nm (A280) and the conductivity are shown as solid and hatched lines, respectively. Brackets indicate fractions that were pooled for further purification. [Diagram 2] Figure 2 shows the second purification step of native Pru p 7 by size exclusion chromatography. The absorbance at 280 nm (A280) and the conductivity are shown as solid and hatched lines, respectively. Brackets indicate fractions that were pooled for further purification. [Diagram 3] Figure 2 shows the third purification step of native Pru p 7, which involved affinity immunoadsorption chromatography using anti-Pru p 3 monoclonal antibody. The absorbance at 280 nm (A280) and conductivity are shown as solid and hatched lines, respectively. Brackets indicate unbound material that was collected for further purification. [Figure 4] The fourth purification step of native Pru p 7 by reversed-phase chromatography. a) Chromatogram with absorbance at 280 nm (A280) and percentage of acetonitrile are shown by solid and hatched lines, respectively. Arrows indicate fractions analyzed by SDS-PAGE and brackets indicate fractions pooled for further analysis. b) SDS-PAGE of fractions is shown in Figure 4a. Lanes 7-9 contain fractions indicated in brackets in Figure 4a. Molecular weights of marker proteins (lane M) are shown on the right. [Diagram 5] Figure 1 shows the first purification step of recombinant Pru p 7 by cation exchange chromatography. The absorbance at 280 nm (A280) and the conductivity are shown as solid and hatched lines, respectively. Brackets indicate fractions that were pooled for further purification. [Figure 6] Second purification step of recombinant Pru p 7 by size exclusion chromatography. a) Chromatograms with absorbance at 280 nm (A280) and conductivity are shown as solid and hatched lines, respectively. Brackets indicate fractions that were pooled for further analysis. b) SDS-PAGE analysis of reduced (lane 1) and non-reduced (lane 2) samples of the pool from the size exclusion chromatography step. Molecular weights of marker proteins (lane M) are indicated on the right. [Figure 7] Figure 2 shows the binding of rabbit anti-Pru p 7 IgG to a) recombinant Pru p 7 and b) Cupressus sempervirens pollen extract at different antiserum dilutions. Pre-immune serum from the same rabbit was used as a negative control. [Figure 8] Figure 1 shows the first step of purification of nCup s GRP from Cupressus sempervirens pollen extract by size exclusion chromatography. The absorbance at 214 nm (A214) and the conductivity are shown as solid and hatched lines, respectively. Brackets indicate fractions that were pooled for further purification. [Figure 9] The second step of the purification of nCup s GRP by ion exchange chromatography is shown. a) Chromatograms with absorbance at 280 nm (A280) and conductivity are shown as solid and dotted lines, respectively. Arrows indicate fractions tested for binding of rabbit anti-Pru p 7 IgG. Brackets indicate fractions pooled for further purification. b) Levels of anti-Pru p 7 IgG binding to the fractions are shown in Figure 9a. c) Silver stained SDS-PAGE of the fractions is shown in Figure 9a. Molecular weights of marker proteins (lane M) are shown on the right. [Figure 10] The third step of the purification of nCup s GRP by size exclusion chromatography is shown. a) Chromatogram with absorbance at 280 nm (A280) is shown as a solid line. Arrows indicate fractions tested for binding of rabbit anti-Pru p 7 IgG and brackets indicate fractions pooled for further purification. b) Levels of anti-Pru p 7 IgG binding to the fractions are shown in Figure 10a. c) SDS-PAGE of the fractions is shown in Figure 10a. Molecular weights of marker proteins (lane M) are shown on the right. d) SDS-PAGE of the pool of fractions is shown in Figure 10a (nCup s GRP, lane 1) and rPru p 7 (lane 2). Molecular weights of marker proteins (lane M) are shown on the right. [Figure 11]Amino acid sequence determination of nCup s GRP by MS / MS. a) The nucleotide sequence of EST record BY878079 (cDNA sequence from the male cone of Cryptomeria japonica) represents the best database match with the MS / MS data obtained from the purified 7 kDa Cupressus sempervirens protein. The start codon (ATG) and stop codons (TGA and TAG) of the interrupted hypothetical open reading frame are underlined. b) The alignment of four peptides (Pep 1-4) was confirmed by MS / MS analysis using the amino acid sequence hypothetically encoded by BY878079. The predicted signal peptide is underlined and the stop codon is indicated by an asterisk. c) The amino acid sequence of Cup s GRP determined by MS / MS with amino acid deviations from the sequence hypothetically encoded by the modified version of BY878079 underlined, confirmed at the two polymorphic sites indicated above the sequence. d) Alignment of the amino acid sequences of Cup s GRP and Pru p 7. Vertical lines, colons, and periods indicate identical, conserved, and semi-conserved positions, respectively. [Figure 12] The third and final purification step of nJun a GRP by size exclusion chromatography is shown. a) Chromatogram with absorbance at 280 nm (A280) and conductivity are shown by solid and hatched lines, respectively. Brackets indicate the pooled fractions of the three absorbance peaks (pools 1-3) shown in the chromatogram. b) SDS-PAGE analysis of selected fractions from size exclusion chromatography is shown in Figure 12a. Fractions including pools 1-3 are shown in brackets. Molecular weights of marker proteins (lanes M) are shown on the right. c) Bar graph shows the levels of rabbit anti-Pru p 7 IgG binding by the three pools shown in Figure 12a. [Figure 13]The third and final purification step of nCry j GRP by size exclusion chromatography. a) Chromatograms with absorbance at 280 nm (A280) and conductivity are shown by solid and hatched lines, respectively. Arrows indicate fractions selected for analysis by SDS-PAGE and binding of rabbit anti-Pru p 7 IgG. Brackets indicate fractions pooled for further purification. b) SDS-PAGE analysis of fractions is shown in Figure 13a. Molecular weights of marker proteins (lane M) are shown on the right. c) Bar graph shows the level of rabbit anti-Pru p 7 IgG binding by fractions shown in Figure 13a. [Figure 14] Amino acid sequence determination of nJun a GRP by MS / MS. a) The nucleotide sequence of the revised version of EST record BY878079 is the best database match with MS / MS data obtained from the purified 7 kDa Juniperus ashei protein. The start codon (ATG), the revised earlier stop codon (TGY), and the terminal stop codon (TAG) of the hypothetical open reading frame are underlined. b) Alignment of four peptides (Pep 1-4) confirmed by MS / MS analysis using the amino acid sequence hypothetically encoded by the revised version of BY878079. The predicted signal peptide is underlined and the stop codon is indicated by an asterisk. c) The amino acid sequence of Jun a GRP determined by MS / MS with amino acid deviations from the sequence hypothetically encoded by the revised BY878079 indicated by underline. d) Alignment of the amino acid sequences of Jun a GRP and Pru p 7. Vertical lines, colons, and periods indicate identical, conserved, and semi-conserved positions, respectively. [Figure 15]Amino acid sequence determination of nCry j GRP by MS / MS. a) The nucleotide sequence of EST record BY900480 (cDNA sequence from the male cone of Cryptomeria japonica) represents the best database match with the MS / MS data obtained from the purified 7 kDa Cryptomeria japonica protein. The start (ATG) and stop (TAG) codons of the hypothetical open reading frame are underlined. b) Alignment of five peptides (Pep 1-5) was confirmed by MS / MS analysis using the amino acid sequence hypothetically encoded by BY900480. The predicted signal peptide is underlined and the stop codon is indicated by an asterisk. c) The amino acid sequence of Cry j GRP was determined by MS / MS. d) Alignment of the amino acid sequences of Cry j GRP and Pru p 7. Vertical lines, colons, and periods indicate identical, conserved, and semi-conserved positions, respectively. [Figure 16] Comparison of sequences and electrophoresis of GRPs from Cupressaceae pollen. a) Multiple alignment of Cup s GRPa, Cup s GRPb, Jun a GRP, and Cry j GRP amino acid sequences. Positions with identical amino acids in all sequences are indicated with an asterisk. b) Matrix comparison of the above amino acid sequences shows the percentage of sequence identity. c) SDS-PAGE of three 7 kDa proteins purified from C. sempervirens (lane 1), J. ashei (lane 2), and C. japonica (lane 3) pollen and recombinant Pru p 7 (lane 4). Molecular weights of marker proteins (lane M) are indicated on the right. [Figure 17] Shown is an SDS-PAGE analysis of rCup s GRPa (lane 1), rCup s GRPb (lane 2), purified native Cup s GRP (lane 3), and rPru p 7 (lane 4). Molecular weights of marker proteins (lane M) are indicated on the left. [Figure 18]Comparison of IgE binding to rPru p 7 and nCup s GRP among 44 peach-allergic subjects. Values ​​below the 0.1 kUA / L limit of quantification (LoQ) of the assay were set at 0.1 kUA / L. The diagonal line indicates a 1:1 slope. [Figure 19] Comparison of IgE binding to nCup s GRP and two variants of recombinant Cup s GRP among 18 peach-allergic subjects: a) rCup s GRPa vs. nCup s GRP, and b) rCup s GRPb vs. nCup s GRP. c) rCup s GRPb vs. rCup s GRPa. The diagonal line indicates a 1:1 slope. [Figure 20] Figure 2 shows inhibition of IgE binding to rPru p 7 by native and recombinant Cup s GRPb in the serum of four different subjects. Results are expressed as a percentage of the dilution buffer control. [Figure 21] Figure 1 shows pairwise comparison of IgE binding between 18 peach-allergic subjects with a) nJun a GRP and nCup s GRP, b) nCry j GRP and nCup s GRP, and c) nCry j GRP and nJun a GRP. The diagonal line indicates a 1:1 slope. [Figure 22] Prevalence and levels of IgE antibodies against nCup s GRP in the serum of 88 subjects sensitized to cypress pollen. Values ​​below the 0.1 kUA / L limit of quantification (LoQ) of the assay (indicated by the diagonal and horizontal lines) were set at 0.5 kUA / L. The diagonal line indicates a slope of 1:1. [Figure 23] Immunological and sequence comparisons between profilins Bet v 2, Cor a 2, Mal d 4, Pru av 4, Pyr c 4, Api g 4, Dau c 4, and Phl p 12. a) Pairwise comparisons compare IgE binding to different profilins. Oblique horizontal and vertical lines indicate 0.35 kUA / L levels, diagonal lines indicate 1:1 slope. b) Pairwise sequence comparisons show percent sequence identity. [Figure 24]Alignment of the Cup s GRPa, Cup s GRPb, Jun a GRP, and Cry j GRP sequences with the Cupressaceae consensus sequence based on these four sequences is shown. Only amino acids that deviate from those of Cup s GRPa are shown in the Cup s GRPb, Jun a GRP, and Cry j GRP sequences. Amino acid positions that show variability are indicated with an X in the Cupressaceae pollen GRP consensus sequence (SEQ ID NO: 9) aligned on top of the other sequences. [Diagram 25] A multiple alignment of 37 known GRP sequences is shown, with asterisks indicating amino acids that are systematically conserved among all sequences compared. [Figure 26] 25. Sequence alignment of Cupressaceae pollen GRP consensus sequence, SEQ ID NO:9, Pru p 7. In row A, amino acid positions marked with Z differ between Cupressaceae pollen GRP and Pru p 7. In row B, amino acids that are conserved between Cupressaceae pollen and Pru p 7 but differ among the 37 sequences aligned as shown in FIG. 25 are shown. In row C, amino acids that are conserved among all 37 aligned sequences are shown. SEQ ID NO:52 is the consensus sequence between Cupressaceae pollen GRP sequences and Pru p 7, with X representing amino acids that are not conserved in this comparison. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] definition The details of the present invention are described below. Although any materials and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred materials and methods are described below. Other features, objects and advantages of the present invention will be apparent from the description. In the description, the singular form includes the plural form unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.

[0033] The terms "protein" and "peptide" should be taken to have their ordinary meaning in the art. Unless otherwise specified, these terms are used interchangeably herein.

[0034] An "isolated" protein refers to a protein that has been separated or removed from its natural environment, and also indicates that it has been produced by human intervention and is substantially separated from coexisting materials in the protein-producing environment.

[0035] Whenever an "isolated protein" or "protein" is referred to herein, this may refer to a fragment or variant of the isolated protein that has sequence identity with the isolated protein further described herein and is functionally equivalent to the original full-length protein. "Functionally equivalent" is further defined elsewhere herein.

[0036] As used herein, the terms "protein", "isolated protein", "allergen protein", "fragment or variant thereof", "fragment or variant of an isolated allergen protein", and "allergen" may be used interchangeably and are contemplated in all contexts and aspects of the present disclosure.

[0037] "Sequence identity" refers to the degree to which two (nucleotide or amino acid) sequences have the same residues at the same positions in an alignment, expressed as a percentage. "Alignment" in this respect refers to the process or result of matching the nucleotide or amino acid residues of two or more biological sequences to achieve the maximum level of identity, in the case of amino acid sequences, to conservation for the purpose of assessing the degree of similarity and possible homology. To determine "overall" sequence identity, the amino acid sequence of each isolated protein compared to its fragment or variant, or the nucleic acid sequence encoding it, can be used for alignment [38, 39].

[0038] The "length" of a protein is the number of amino acid residues in the protein.

[0039] As used herein, a "fragment" of a protein should be construed to mean a fragment having at least 85% sequence identity with the amino acid sequence of the original protein, calculated over the entire length of the original protein. In other words, according to the present disclosure, at least 85% of the amino acid residues of the full-length original protein are present in the fragment. As disclosed herein, the original protein may have an amino acid sequence according to SEQ ID NO: 4. As a result, a "fragment" disclosed herein may have at least 85% identity with the amino acid sequence of SEQ ID NO: 4, calculated over the entire length of SEQ ID NO: 4. Protein fragments may further comprise additional amino acids as a result of their production, such as a hexahistidine tag, a linker sequence, or vector-derived amino acids.

[0040] A "variant" of a protein refers to a variant that has at least 85% sequence identity with the amino acid sequence of the original protein, as calculated over the entire length of the variant protein. The original protein may have an amino acid sequence according to SEQ ID NO: 4. As a result, the "variant" disclosed herein may have at least 85% identity with the amino acid sequence of SEQ ID NO: 4. There are many software tools available commercially for aligning original and variant proteins and calculating sequence identity, such as Clustal Omega provided by the European Bioinformatics Institute (Cambridge, United Kingdom). Protein variants may further include additional amino acids as a result of their production, such as hexahistidine tags, linker sequences, or vector-derived amino acids.

[0041] Whenever reference is made herein to a "functionally equivalent protein fragment or variant" of a protein, or a "functionally equivalent fragment or variant" of a protein, this is intended to mean that the protein and its fragment or variant have equivalent IgE-binding properties. More particularly, to be a functionally equivalent variant or fragment of the original isolated allergen protein: (a) the variant or fragment inhibits binding of IgE antibodies from a representative patient serum sample sensitized to the original allergen protein by the original allergen protein by at least 50% compared to mock inhibition with buffer alone (IgE diluent, Thermo Fisher Scientific). This property of the variant or fragment can be assayed by using any suitable inhibition assay known in the art, for example as described in Example 9. (b) the variant or fragment binds to IgE antibodies at substantially the same level as the original allergen protein. The level of binding can be measured, for example, by immobilizing the variant or fragment on a solid phase, measuring the IgE reactivity of an individual's serum, and comparing the measured IgE reactivity to the IgE reactivity of the original isolated allergen protein, as described in Example 8. For the purposes of this definition, "substantially the same level" should be taken to mean that the binding level of the variant differs from the binding level of the original protein by at most 25%, 20%, 15%, 10%, or 5%. (c) A variant or fragment that includes all the conserved amino acids of the Cupressaceae GRP consensus sequence (i.e., SEQ ID NO: 9; see FIG. 26 for conserved amino acids): (d)(i) if it is a variant, the variant has up to 9 amino acid residues exchanged compared to SEQ ID NO: 4, such as 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residue(s) exchanged compared to SEQ ID NO: 4; or (ii) if it is a fragment, the fragment has up to 9 amino acid residues deleted compared to SEQ ID NO: 4, such as 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residue(s) deleted compared to SEQ ID NO: 4; or (iii) If it is a combination of variants and fragments, the combination of variants and fragments has a maximum of 9 amino acid residue exchanges or deletions compared to SEQ ID NO:4.

[0042] Examples 10 and 12 show that IgE binding of allergen proteins due to cross-reactivity is very similar between closely related allergen proteins within the same protein family: Homologous proteins that share at least 80%, e.g., 90% or more sequence identity with each other, show remarkably similar IgE reactivity.

[0043] An amino acid residue at a particular position of an amino acid sequence is described as "systematically conserved" or sometimes simply "conserved" between different proteins of the same protein family if the amino acid residue at that position is identical between the aligned protein sequences compared. Thus, amino acid residues that are not "conserved" between different proteins are not identical between the compared protein sequences. Non-conserved amino acid residues may be "systematically restricted" or have "systematically restricted variability" across the compared protein sequences, which is intended to mean that the amino acid at a particular position is selected from a group consisting of a limited number of amino acids found in a systematic comparison of a group of similar proteins, for example, from the GRP protein family.

[0044] The term "vector" or "expression vector" refers to a DNA molecule used as a vehicle to artificially transport foreign genetic material into another cell so that it can be replicated and / or expressed therein.

[0045] "Host cell" refers to a bacterial, yeast, insect, or mammalian cell that has been transformed with a vector disclosed herein to express a protein, fragment, or variant of interest.

[0046] A protein "isoform" is a member of a group of highly similar proteins, resulting from genetic variation, either as allelic variants of a single gene or as non-identical members of a gene family. Many isoforms perform the same or similar biological functions.

[0047] Detailed Description As previously described herein, the inventors have succeeded for the first time in identifying the Cupressaceae pollen protein corresponding to Pru p 7, which is believed to be the primary sensitizer for severe peach allergy mediated by Pru p 7 (see the results presented in Example 8). Isolation of highly pure Pru p 7 from natural sources was a prerequisite for obtaining truly specific anti-Pru p 7 rabbit antisera. Since the Pru p 7 protein has biochemical properties similar to those of Pru p 3, as evidenced by the demonstration of Pru p 7 contamination in commercial preparations of Pru p 3

[34] , an elaborate purification method was developed for this purpose, including a biospecific affinity adsorption to remove Pru p 3, and a reversed-phase chromatography (RPC) step to remove other co-purifying proteins (see Example 1). Anti-Pru p 7 antisera obtained by immunizing rabbits with a highly purified native Pru p 7 preparation can further be used to detect Pru p 7 homologues in elution fractions of Cupressus sempervirens, Cryptomerica japonica, and Juniperus ashei pollen extracts. In contrast to what might be expected in view of the previously reported 14 kDa BP14 protein from C. sempervirens previously mentioned herein, rabbit anti-Pru p 7 IgG antibodies detected only a 7 kDa protein (i.e., a protein half the size of BP-14) in C. sempervirens pollen extracts, as well as in pollen extracts of Juniperus ashei and Cryptomeria japonica. Once identified, these proteins can be purified to homogeneity for analysis by mass spectrometry and biochemical and immunological characterization.

[0048] By combining the N-terminal sequencing data, MS / MS data from different enzymatic digests of each preparation, and the interrupted / incomplete EST sequence from Cryptomeria japonica in an iterative process, the complete amino acid sequence of the 7 kDa protein could be deduced / embedded together from Cupressus sempervirens and Juniperus ashei. The complete sequence of the Pru p 7 homologue from Cryptomeria japonica was determined by analyzing the MS / MS data in the EST database. The immunological similarity between the three native Cupressaceae pollen allergens is demonstrated and discussed in Example 10.

[0049] Another prerequisite of the present project was the development of a methodology for producing correctly folded, immunoreactive recombinant GRP allergens in practically useful quantities. This involved the investigation of various expression systems, vector cloning variants, and fermentation strategies for the production of rPru p 7 and rCup s GRPs. Although several initial attempts following different standard procedures generated biochemically and immunologically defective protein products, the methodology finally elaborated was highly successful in terms of both quality and yield.

[0050] Based on the sequence of Cup s GRP established and disclosed herein, recombinant Cup s GRP was produced in Pichia pastoris and shown to have similar biochemical properties and IgE reactivity as the native purified protein. The recombinant protein inhibited IgE binding to Pru p 7, indicating that there is cross-reactivity between the peach protein Pru p 7 and Cup s GRP, with the latter acting as a primary sensitizer.

[0051] The identification of this protein and its subsequent recombinant production paves the way for new and improved diagnosis of allergy type 1. Because of the established association between severe peach allergy and cypress pollen allergy, the currently disclosed findings may have applications in the diagnosis, treatment, and / or prevention of both pollen and food allergies.

[0052] As mentioned herein, over the years, there have been many attempts to identify, isolate and characterize allergen proteins of the gibberellin-regulated protein family from pollen.Despite the presumed understanding of the importance of pollen allergens in this protein family, no one has done so until the present disclosure successfully isolated and described the complete sequence of such a protein.As mentioned herein, fragments of sequence information have been reported before, but the complete sequence, the structure of the protein and how it compares with other members of the same protein family, and the requirements for generating recombinant proteins for diagnostic and therapeutic applications remain to be elucidated.

[0053] The lack of progress to date indicates the difficulty of identifying and isolating proteins of this protein family from pollen. In particular, the inventors have discovered a way to solve this problem. By way of example, it has taken substantial inventive effort to identify functional experimental protocols that result in the provision of complete details of the proteins described herein, as well as methods to obtain and apply the discoveries gained through the isolation and characterization process. However, ultimately, the allergen proteins have been isolated, evaluated, and utilized, as further shown and described herein.

[0054] Thus, provided herein is an isolated allergen protein comprising an amino acid sequence according to SEQ ID NO: 4, or a functionally equivalent protein fragment or variant thereof having at least 85% sequence identity with SEQ ID NO: 4. Furthermore, said sequence identity with SEQ ID NO: 4 may be at least 90%, e.g. 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0055] The isolated proteins are represented and exemplified herein by the highly homologous proteins Cup s GRP (protein isoform a (SEQ ID NO: 4) and protein isoform b (SEQ ID NO: 5)), Jun a GRP (SEQ ID NO: 6) and Cry j GRP (SEQ ID NO: 8).

[0056] The amino acid sequence of Pru p 7 (Pru p7) comprises the following sequence: [Sequence Table 1] TIFF0007618641000001.tif15152 SEQ ID NO:1 (nPru p 7)

[0057] The amino acid sequence of Cup s GRPa comprises the following sequence: [Sequence Table 2] TIFF0007618641000002.tif14153 SEQ ID NO:4 (Cup s GRPa)

[0058] The amino acid sequence of Cup s GRPb comprises the following sequence: [Sequence Table 3] TIFF0007618641000003.tif15153 SEQ ID NO:5 (Cup s GRPb)

[0059] The amino acid sequence of Jun a GRP comprises the following sequence: [Sequence Table 4] TIFF0007618641000004.tif13153 SEQ ID NO:6 (Jun a GRP)

[0060] The amino acid sequence of Cry j GRP comprises the following sequence: [Sequence Table 5] TIFF0007618641000005.tif15153 SEQ ID NO:8 (Cry j GRP)

[0061] As described and shown in Example 13 below, a Cupressaceae-Pru p 7 GRP consensus sequence (SEQ ID NO:52) has been designed and is disclosed herein. In the consensus sequence according to SEQ ID NO:52, positions where amino acids vary between the different Cupressaceae pollen GRPs disclosed herein (i.e., Cup s GRPa, Cup s GRPb, Jun a GRP, and Cry j GRP), as well as positions where amino acids vary between the Cupressaceae pollen GRPs disclosed herein and peach GRPs (i.e., Pru p 7) are indicated with an X (Figure 26). In row A of Figure 26, positions where amino acids vary between the Cupressaceae pollen GRPs disclosed herein and peach GRPs (i.e., Pru p 7) are indicated with a Z. [Sequence Table 6] TIFF0007618641000006.tif54156

[0062] Accordingly, the present disclosure provides an isolated allergen protein, the protein comprising the following amino acid sequence according to SEQ ID NO:52: [Sequence Table 7] TIFF0007618641000007.tif44154, wherein up to nine, e.g., 9, 8, 7, 6, 5, 4, 3, 2, or 1 of the positions X include any amino acid as defined in Table 3; In the remaining positions X, isolated allergen proteins are provided in which the amino acid is identical to the amino acid in the corresponding position of SEQ ID NO:4.

[0063] In particular, the present disclosure relates to an isolated allergen protein, the protein comprising the following amino acid sequence according to SEQ ID NO:52: [Sequence Table 8] TIFF0007618641000008.tif48160, where up to four of positions X include any amino acid as defined in Table 3; In the remaining positions X, isolated allergen proteins are provided in which the amino acid is identical to the amino acid in the corresponding position of SEQ ID NO:4.

[0064] Note that the amino acid residues listed in Table 3 are those that have systematically restricted variability at position X of SEQ ID NO:52.

[0065] Further provided are functionally equivalent protein fragments or variants of SEQ ID NO:5, 6, or 8, respectively, which have at least 85% sequence identity to SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:8, respectively. Moreover, the sequence identity to SEQ ID NO:5, 6, or 8 can be at least 90%, e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0066] The amino acid sequences of these exemplified isolated proteins from the Cupressaceae family differ from each other only at up to seven amino acid positions, as shown in SEQ ID NO:9. A sequence alignment showing the differences and similarities between the above family members is shown in FIG. 24. In Example 10 herein, it was demonstrated that changing the amino acid residues at least at these positions does not affect the functionality of the proteins for their intended purpose. Thus, it shows a degree of structural flexibility in the amino acid sequence, which means that functionally equivalent variants or fragments of the isolated protein shown by SEQ ID NO:4 are envisioned and will prove useful in the context of the present disclosure. The definition of the functionally equivalent variants or fragments of the isolated protein according to SEQ ID NO:4 presented herein is described elsewhere herein.

[0067] Thus, the present disclosure further provides an isolated allergen protein, said protein comprising the following amino acid sequence according to SEQ ID NO:9: [Sequence Table 9] TIFF0007618641000009.tif46160 Herein, there is provided an isolated allergen protein, wherein any position X comprises any amino acid, with the proviso that X is not C.

[0068] When it is stated herein that position X (any of) in SEQ ID NO:9 or SEQ ID NO:52 may contain "any amino acid", this expression is intended to mean any natural or non-naturally occurring amino acid. In particular, it is disclosed herein that position X (any of) in SEQ ID NO:9 or SEQ ID NO:52 may contain any naturally occurring amino acid.

[0069] SEQ ID NO: 9 can be considered as an example of a Cupressaceae pollen GRP consensus sequence representing the isolated protein identified herein, wherein the amino acid residues in up to seven amino acid positions (positions 2, 18, 31, 34, 41, 46, and 52) can be varied, i.e., exchanged, at one or more positions for any other amino acid, provided that X is not C, and that such protein maintains a functionally equivalent activity to the original protein for the intended purpose described elsewhere herein. Also contemplated herein are other variants of SEQ ID NO: 4 having the same sequence similarity, but with additional or alternative amino acid residues varied, such that the variant maintains the same functional activity as the original protein, i.e., the variant is functionally equivalent to the original protein, or to a protein in which the amino acids at the above seven positions are varied as further described herein. Also provided herein are functionally equivalent fragments of the isolated protein according to SEQ ID NO: 9.

[0070] As shown in Example 13, at the seven amino acid positions X, it is envisaged that the amino acid is selected from the group consisting of systematically restricted amino acids.

[0071] According to FIG. 25, the following amino acids are systematically preferred at each position X of SEQ ID NO:9: Position 2: AESDTLY Position 18: YLIVFMR Position 31:EDQAGSK Position 34:QNHK Position 41:YFAS Position 46: EVAQ Position 52:DEN

[0072] All of the preferred amino acid residues disclosed above at position X have systematically limited variability from one another, consistent with that found in the known GRP sequences aligned in FIG.

[0073] Furthermore, according to the sequences of Cupressaceae pollen GRP proteins, the following amino acids are systematically preferred at each position X of SEQ ID NO:9: X in position 2 is Q or H; X at position 18 is A or L; X at position 31 is K or E; X at position 34 is H or N; X at position 41 is A or Y; X at position 46 is V or S; and / or X at position 52 is H or N.

[0074] The amino acid residues disclosed above have systematically restricted variability and are consistent with those found in Cupressaceae pollen GRPs, namely Cups GRPa, Cups GRPb, Juna GRP, and Cryj GRP, as shown in the alignment in FIG. 24.

[0075] Thus, there is provided herein an isolated allergen protein comprising an amino acid sequence according to SEQ ID NO: 9, wherein up to 6, such as 5, 4, 3, 2 or 1 of said positions X of SEQ ID NO: 9 comprise any amino acid, with the proviso that X is not C, In the remaining position(s) X, the amino acid is X at position 2 is selected from any one of Q, H, A, E, S, D, T, L, or Y; X at position 18 is selected from any one of A, L, Y, I, V, F, M, or R; X at position 31 is selected from any one of K, E, D, Q, A, G, or S; X at position 34 is selected from any one of H, N, Q, or K; X at position 41 is selected from any one of A, Y, F, or S; X at position 46 is selected from any one of V, S, E, V, A, or Q; and / or An isolated allergen protein is provided, wherein X at position 52 is selected from the group of amino acids selected from any one of H, N, D, or E.

[0076] In particular, provided herein is an isolated allergen protein comprising an amino acid sequence according to SEQ ID NO: 9, wherein up to four, such as three, two or one of said positions X of SEQ ID NO: 9 comprise any amino acid, with the proviso that X is not C, In the remaining position(s) X, the amino acid is X at position 2 is selected from any one of Q, H, A, E, S, D, T, L, or Y; X at position 18 is selected from any one of A, L, Y, I, V, F, M, or R; X at position 31 is selected from any one of K, E, D, Q, A, G, or S; X at position 34 is selected from any one of H, N, Q, or K; X at position 41 is selected from any one of A, Y, F, or S; X at position 46 is selected from any one of V, S, E, V, A, or Q; and / or An isolated allergen protein is provided, wherein X at position 52 is selected from the group of amino acids selected from any one of H, N, D, or E.

[0077] Further provided herein is an isolated allergen protein comprising an amino acid sequence according to SEQ ID NO:9, wherein up to 6, e.g. 5, 4, 3, 2 or 1 of said positions X of SEQ ID NO:9 comprise any amino acid, with the proviso that X is not C, In the remaining positions X, the amino acid is X at position 2 is selected from any one of Q and H; X at position 18 is selected from any one of A or L; X at position 31 is selected from any one of K or E; X at position 34 is selected from any one of H or N; X at position 41 is selected from any one of A and Y; X at position 46 is selected from any one of V or S; and An isolated allergen protein is provided, wherein X at position 52 is selected from the group of amino acids selected from any one of H or N.

[0078] In particular, provided herein is an isolated allergen protein comprising an amino acid sequence according to SEQ ID NO: 9, wherein up to four, such as three, two or one of said positions X of SEQ ID NO: 9 comprise any amino acid, with the proviso that X is not C, In the remaining positions X, the amino acid is X at position 2 is selected from any one of Q and H; X at position 18 is selected from any one of A or L; X at position 31 is selected from any one of K or E; X at position 34 is selected from any one of H or N; X at position 41 is selected from any one of A and Y; X at position 46 is selected from any one of V or S; and An isolated allergen protein is provided, wherein X at position 52 is selected from the group of amino acids selected from any one of H or N.

[0079] More particularly, the present invention relates to an isolated allergen protein comprising an amino acid sequence according to SEQ ID NO: 9, wherein in position X, the amino acid X at position 2 is selected from any one of Q, H, A, E, S, D, T, L, or Y; X at position 18 is selected from any one of A, L, Y, I, V, F, M, or R; X at position 31 is selected from any one of K, E, D, Q, A, G, or S; X at position 34 is selected from any one of H, N, Q, or K; X at position 41 is selected from any one of A, Y, F, or S; X at position 46 is selected from any one of V, S, E, V, A, Q, and / or An isolated allergen protein is provided, wherein X at position 52 is selected from the group of amino acids selected from any one of H, N, D, or E.

[0080] Further provided herein is an isolated allergen protein comprising an amino acid sequence according to SEQ ID NO:9, X in position 2 is Q or H; X at position 18 is A or L; X at position 31 is K or E; X at position 34 is H or N; X at position 41 is A or Y; X at position 46 is V or S; and / or An isolated allergen protein is provided, wherein X at position 52 is H or N.

[0081] Further provided herein is an isolated allergen protein comprising an amino acid sequence according to SEQ ID NO:9, wherein up to four, such as three, two or one of said positions X of SEQ ID NO:9 are X at position 2 is selected from any one of Q, H, A, E, S, D, T, L, or Y; X at position 18 is selected from any one of A, L, Y, I, V, F, M, or R; X at position 31 is selected from any one of K, E, D, Q, A, G, or S; X at position 34 is selected from any one of H, N, Q, or K; X at position 41 is selected from any one of A, Y, F, or S; X at position 46 is selected from any one of V, S, E, V, A, Q, and / or X at position 52 comprises an amino acid selected from the group of amino acids selected from any one of H, N, D, or E; In the remaining positions X, isolated allergen proteins are provided in which the amino acid is identical to the amino acid in the corresponding position of SEQ ID NO:4.

[0082] More particularly, the present invention relates to an isolated allergen protein comprising an amino acid sequence according to SEQ ID NO: 9, wherein up to four, such as three, two or one of said positions X of SEQ ID NO: 9 are X in position 2 is Q or H; X at position 18 is A or L; X at position 31 is K or E; X at position 34 is H or N; X at position 41 is A or Y; X at position 46 is V or S; and / or An isolated allergen protein is provided, wherein X at position 52 is H or N.

[0083] In particular, the present disclosure further provides isolated allergen proteins comprising or consisting of an amino acid sequence according to SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:8, respectively.

[0084] The proteins described herein can also add chemically modified amino acids to the original sequence, which refers to amino acids whose side chains are chemically modified. For example, the side chains can be modified to include signaling moieties such as fluorophores or radioactive labels. The side chains can be modified to include new functional groups such as thiols, carboxylic acids, or amino groups. Post-translationally modified amino acids are also included in the definition of chemically modified amino acids.

[0085] The isolated proteins, variants or fragments thereof disclosed throughout this specification may be produced recombinantly. In general, the practical use of allergen proteins in research, diagnostic or other applications is greatly facilitated by their availability in recombinant form. Once an allergen protein has been identified and its amino acid sequence established, it can be produced as a recombinant protein using well-known methods

[40] ). However, in difficult cases that do not behave as textbook examples, it may be necessary to extensively adapt or even develop de novo the expression system configuration, culture method, and / or purification strategy to achieve the goal of obtaining useful quantities of functional protein. How such extensive adaptations are achieved cannot be easily foreseen even by those skilled in the art. Genes encoding proteins can be cloned in the form of cDNA derived from mRNA prepared from allergen source material or synthesized according to the desired DNA sequence. Due to the redundancy of the genetic code, with up to six different codons specifying the same amino acid, a given amino acid sequence can be encoded by a large number of synonymous DNA sequences. If necessary, functional additions or modifications to the protein can be introduced through the design of synthetic genes, by site-directed mutagenesis, or as part of the cloning strategy. Genes encoding the allergen of interest are cloned into any of a variety of different expression vectors and introduced into any of a variety of prokaryotic or eukaryotic expression hosts.

[40] Common expression hosts include, but are not limited to, the gram-negative bacterium Escherichia coli, the yeasts Saccharomyces cerevisiae and Pichia pastoris, insect cell lines derived from Spodoptera frugiperda or Drosophila melanogaster, and mammalian cell lines.

[0086] Recombinant proteins can be expressed intracellularly in soluble or insoluble form or secreted into culture medium. Recombinant protein recovery and purification can be carried out by various well-known methods or their combinations. Common chromatographic techniques include immobilized metal ion affinity chromatography (IMAC), anion and cation exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography, size exclusion chromatography.

[0087] The isolated proteins presented herein, when recombinantly produced, may be purposefully modified for a specific purpose, resulting in a non-naturally occurring protein without functionally affecting the protein, for example, in terms of antibody binding properties. A non-naturally occurring protein may be a recombinant protein fused with another protein to increase expression levels or solubility. Examples of such fusion partners include thioredoxin (TRX), maltose binding protein (MBP), and glutathione-S-transferase (GST). Another example is the addition of a signal peptide that allows the protein to be secreted into the culture medium, from which it can be easily recovered in soluble form. A non-naturally occurring protein may also be a recombinant protein in which a short peptide tag has been genetically grafted onto the protein to allow affinity purification. Examples of such peptide tags include hexahistidine to confer metal ion affinity, or peptide epitopes for specific antibodies, such as anti-hemagglutinin, anti-c-myc, or anti-Flag monoclonal antibodies.

[0088] To allow for the separation and removal of such additions to recombinant proteins, short peptide sequences for site-specific proteolytic cleavage can be inserted between the protein of interest and the fusion partner or peptide tag. Examples of such target sites for proteolytic enzymes include DDDDK of enterokinase, IEGR of factor Xa, ENLYFQA of TEV protease, and EKREAEAEF of Kex2 / Ste13 for in vivo processing in P. pastoris. Some amino acid residues of such target sequences may remain after cleavage, for example, EAEFEF or parts thereof in the case of secretory expression in P. pastoris.

[0089] Also provided herein is an isolated nucleic acid molecule encoding the isolated protein, fragment or variant disclosed herein. The isolated nucleic acid may be encoded by SEQ ID NO: 10. SEQ ID NO: 10 is a degenerate DNA sequence encoding the consensus Cupressaceae amino acid sequence (i.e., SEQ ID NO: 9), which is based on the CupsGRPa, CupsGRPb, JunaGRP, and CryjGRP sequences described herein, i.e., the isolated proteins disclosed herein, including synonymous codons and variants according to the IUPAC ambiguity code. The consensus Cupressaceae nucleic acid sequence according to SEQ ID NO: 10 was constructed starting from the CupsGRPa amino acid sequence (i.e., SEQ ID NO: 4), reverse-translated, including synonymous codons, and considering the seven amino acid positions where CupsGRPb, JunaGRP, and / or CryjGRP differ from the CupsGRPa amino acid sequence. The nucleotides encoding the seven variable amino acid positions are marked in bold text below.

[0090] SEQ ID NO:10, the Cupressaceae consensus nucleic acid sequence: [Sequence Table 10] TIFF0007618641000010.tif22169, where N=T, C, A, or G; R=A or G; H=T, C, or A; Y=T or C; M=C or A; W=T or A; S=G or C; B=C, G, or T; K=G or T; and D=A, G, or T.

[0091] Also provided herein are the following nucleic acid sequences: SEQ ID NO: 50, i.e. Cup s GRPa, is reverse translated and takes into account synonymous codons: [Sequence Table 11] TIFF0007618641000011.tif18160

[0092] SEQ ID NO:51, i.e., Cup s GRPa, has been reverse translated and the nucleotides encoding the seven variable amino acid positions (marked in bold) have been changed to nucleotides encoding amino acids present in Cup s GRPb, Jun a GRP, and / or Cry j GRP: [Sequence Table 12] TIFF0007618641000012.tif19160

[0093] In SEQ ID NO:50 and SEQ ID NO:51, the variable nucleotides have the same meaning as in SEQ ID NO:10, as defined above.

[0094] Also provided herein is a nucleic acid molecule comprising a nucleic acid sequence according to any one of SEQ ID NOs: 10, 50, or 51, or a sequence having at least 85% sequence identity thereto, for example at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0095] Also provided is a vector or expression vector comprising an isolated nucleic acid molecule disclosed herein. The isolated nucleic acid molecule may encode an isolated protein disclosed herein or a fragment or variant thereof, and thus may comprise or consist of any nucleic acid sequence disclosed herein.

[0096] Also provided is an isolated host cell comprising a vector or expression vector as described herein, as previously described herein, the vector or expression vector comprising a nucleic acid molecule encoding the isolated protein, or a fragment or variant thereof, as disclosed elsewhere herein.

[0097] A method for producing an allergen composition is provided, comprising adding an isolated protein or a functionally equivalent fragment or variant as described herein to a composition comprising an allergen extract and / or at least one purified allergen component. An allergen composition obtained by such a method is also provided. Such an allergen composition can be "spiked" with an isolated protein, a fragment or variant thereof as presented herein. Such an allergen composition can be an allergen extract or a mixture of purified or recombinant allergen components that does not contain or has a low content of an isolated protein as presented herein, to which an isolated protein, a fragment or variant thereof is added (i.e., the allergen composition is "spiked") in order to bind IgE from patients whose IgE does not otherwise bind or binds poorly to the allergen composition. Thus, this aspect relates to a method for producing such a composition, comprising adding said protein to an allergen composition such as an allergen extract (optionally as mentioned with other components spiked) or a mixture of purified natural or recombinant allergen components. Also provided are allergen compositions comprising an isolated protein as described herein, or a fragment or variant thereof, and an allergen extract and / or at least one purified allergen component.

[0098] There is also provided herein the use of the isolated protein, or a functionally equivalent fragment or variant thereof, for the in vitro diagnosis or assessment of type 1 allergy.

[0099] The present specification also provides for use when the type 1 allergy symptoms are induced by pollen of Cupressaceae species.Furthermore, the present specification also provides for use when the type 1 allergy is pollen-related food allergy with symptoms induced by foods such as peaches, apricots, plums, citrus fruits or pomegranates.

[0100] The detection or measurement of allergen-specific IgE antibodies in human or animal specimens can be performed in several different ways, but usually involves an initial step of capturing antibodies that bind to the allergen in question, followed by a washing step to remove unbound antibodies, a step of applying an IgE detection reagent, a washing step to remove unbound such reagent, and a final step of generating and recording a signal from the IgE detection reagent. The allergen can be immobilized on a solid or soluble support to capture the allergen-specific antibodies, or can form a complex with the antibody in solution for subsequent capture and quantification of such complexes. The allergen detection reagent is usually a monoclonal antibody conjugated to either a reporter substance or an enzyme capable of catalyzing the formation of a product quantifiable by fluorescent or colorimetric methods. Assays for measuring allergen-specific antibodies also include a calibration system capable of converting primary response units into antibody concentration units. The same assay principle applies to the measurement of allergen-specific antibodies of other isotypes, the only difference being the specificity of the detection reagent used.

[0101] Further provided herein is a method for in vitro diagnosis or assessment of type 1 allergy, comprising contacting an immunoglobulin-containing body fluid sample from a subject suspected of having type 1 allergy with an isolated allergen protein, or a fragment or variant thereof, as described herein, and determining the presence in the sample of an antibody, such as an IgE antibody, that specifically binds to the protein, fragment or variant thereof, wherein the presence of an antibody in the sample that specifically binds to the protein is indicative of type 1 allergy in the subject. In one embodiment where an IgE antibody is present in the sample and specifically binds to the protein, this is indicative of type I allergy in the subject.

[0102] The bodily fluid sample may be a blood or serum sample from a subject, and the bodily fluid sample is contacted with the isolated protein, or a fragment or variant thereof, or a composition comprising the protein, or a fragment or variant thereof, to determine whether the subject sample contains IgE antibodies that specifically bind to the isolated protein, variant, or fragment thereof.

[0103] A fragment or variant of any isolated protein referred to herein may be a naturally occurring or artificial fragment or variant that is functionally equivalent to the original protein.

[0104] Further provided is a kit-of-parts comprising an isolated allergen protein, or fragment or variant, soluble or immobilized on a solid support, said kit optionally further comprising a detection reagent and / or instructions for use. The solid support may be selected from the group of nitrocellulose, glass, silicon and plastic, and / or is a microarray chip or any other suitable solid support available in the art.

[0105] As mentioned elsewhere herein, the kit may further comprise a detection agent capable of binding to an antibody, such as an IgE antibody, bound to the immobilized protein. Such a detection agent may be, for example, an anti-IgE antibody labeled with a detectable label, such as a dye, fluorophore or enzyme, as are well known in the art of immunoassays.

[0106] Supports suitable for immobilizing proteins and peptides are well known in the art, and in this specification, in this embodiment, include any support that does not adversely affect the immunogenicity of the protein or protein fragment to a substantial extent.In this context, it is understood that the term "immobilized" can be any type of attachment suitable for a particular support.Isolated proteins or protein fragments can be immobilized on solid supports suitable for use in diagnostic methods such as ImmunoCAP, EliA, or VarelisA.Alternatively, proteins or protein fragments can be immobilized on natural or synthetic polymer structures in solution, such as one or more dendritic structures in solution.

[0107] Also provided herein is the isolated protein, fragment or variant thereof described herein, which is provided with a label or labeling element.Thus, also provided herein is a protein, fragment or variant of a protein, which is provided with a luminescent label, such as a light-emitting label, a fluorescent label or a phosphorescent label, a chemiluminescent label or a radioluminescent label.Also included in the present disclosure is the isolated protein, fragment or derivative thereof, which is derivatized with an identifiable element, such as an affinity function.Affinity functions for labeling proteins and peptides are well known in the art, and the skilled artisan will be able to select any suitable function, such as biotin.

[0108] Also provided herein is an isolated protein or a functionally equivalent fragment or variant thereof for use in treating or preventing type 1 allergy. Type 1 allergy can be caused by pollen of Cupressaceae species, and / or can be Cupressaceae pollen-related food allergy with symptoms induced by eating fruits such as peaches, apricots, plums, citrus fruits, or pomegranates. Also provided is the use of the isolated protein or a functionally equivalent fragment or variant disclosed herein in the manufacture of a medicament for treating or preventing type 1 allergy. Type 1 allergy can be caused by pollen of Cupressaceae species, and / or can be Cupressaceae pollen-related food allergy with symptoms induced by eating fruits such as peaches, apricots, plums, citrus fruits, or pomegranates.

[0109] Further provided herein is a pharmaceutical composition comprising an isolated protein or a functionally equivalent fragment or variant thereof, and a pharma- ceutically acceptable carrier and / or excipient.

[0110] Pharmaceutically acceptable carriers and / or excipients herein refer to pharma- ceutically acceptable materials, compositions, or vehicles, such as liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials. Each component must be "pharma- ceutically acceptable" in the sense of being compatible with the other components of the formulation. It must also be suitable for use in contact with human and animal tissues or organs without undue toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0111] Also provided herein is a method for the treatment or prevention of type 1 allergy, comprising administering to a subject in need thereof a pharma- ceutical effective amount of the isolated protein, fragment or variant thereof, allergen composition, or composition comprising said isolated protein, fragment or variant thereof, as described herein. The use of the protein, variant or fragment thereof in immunotherapy includes, for example, component-resolved immunotherapy

[41] . The isolated protein can be used in its native form or in a recombinant form that exhibits similar biochemical and immunological properties as the native protein. The isolated protein can be used in modified form, which is produced chemically or genetically. Examples of modifications to the isolated protein include, but are not limited to, fragmentation, truncation, tandemerization or aggregation of the protein, deletion of internal segments(s), substitution(s) of amino acid residues, rearrangement of domains, or disruption of at least a portion of the tertiary structure by disrupting disulfide bridges or binding it to another macromolecular structure or other low molecular weight compounds.

[0112] Any suitable method of administration of the pharmaceutical compositions disclosed herein can be used depending on the purpose of administration of the isolated protein. The dosage and timing of administration will be determined by a physician as appropriate for the subject being treated.

[0113] As mentioned elsewhere herein, the protein can be purified from its natural source. It can also be produced by recombinant DNA technology or chemically synthesized by methods known to those skilled in the art or as described in this application.

[0114] Further provided herein is a method wherein the type 1 allergy is a type 1 allergy caused by pollen of a Cupressaceae species, and / or a Cupressaceae pollen-related food allergy with symptoms induced by ingestion of fruits such as peaches, apricots, plums, citrus fruits, or pomegranates.

[0115] The following examples further illustrate the invention but should not be construed as limiting the invention which is defined by the appended claims.

[0116] Experimental Section table Table 1 below identifies the SEQ ID NOs from the sequence listing which is part of this disclosure, and the corresponding definitions / names of the sequences. [Table 1]

[0117] Table 2: List of peptide sequences identified by MS / MS analysis of a) nCup s GRP, b) isoform variants of nCup s GRP, c) nJun a GRP, and d) nCry j GRP. Column 1 shows the sequence of the peptide, column 2 the corresponding sequence number, column 3 the statistical significance value -logP, column 4 the experimentally determined mass of the peptide in Da (M / Z -1.00794), column 5 the experimentally determined mass corrections for biological or experimental modifications (PTMs), column 6 the theoretically calculated mass of the peptide, columns 7-8 the start and end positions of the amino acid sequence of the mature protein that the peptide represents, and column 9 the modifications present in the analyzed peptides. Prior to MS / MS analysis, all cysteine ​​residues were modified to propionamide residues resulting in an increase in mass of 71.03712 Da per cysteine ​​residue. In some peptides, amidation of the terminal glutamic acid occurred, causing a mass loss of 0.984 Da, as shown below in column 9. In the context of this MS / MS analysis, biological or experimental amino acid modifications are referred to as PTMs. [Table 2] [Table 3] [Table 4] [Table 5]

[0118] Table 3 identifies amino acids with systematically restricted variability at position X of SEQ ID NO:52, ie, the Cupressaceae-Pru p 7 GRP consensus sequence having 21 variable positions. [Table 6]

[0119] The amino acids at positions 1, 3, 4, 7, 8, 10, 11, 17, 19, 20, 44, 51, 59, and 60 are conserved among the four Cupressaceae GRP proteins disclosed herein but differ from the amino acids at the corresponding positions in Pru p 7. The positions are designated by a Z in row A of Figure 26 but by an X in SEQ ID NO:52.

[0120] Amino acids at positions 2, 18, 31, 34, 41, 46, and 52 differ among the four Cupressaceae GRP proteins disclosed herein. The positions are designated with an X in both SEQ ID NO:9 and SEQ ID NO:52. EXAMPLES

[0121] Unless otherwise stated, all filters, chromatographic media, and equipment were obtained from GE Healthcare Life Sciences, Uppsala, Sweden.

[0122] Example 1: Preparation of native Pru p 7 from canned peaches Purification of native Pru p 7 Native Pru p 7 was purified from canned peaches using four chromatographic steps. In other words, canned peaches were mixed in a kitchen blender in 130 mM NaAc pH 4.5 and incubated with grinding balls (Haldenwanger MTC, Berkshire, UK) at 4 °C for 2 h with stirring. The extract was clarified by centrifugation, filtered and loaded onto a SP Sepharose FF column equilibrated in 130 mM NaAc pH 4.5. Washing and elution were performed with isocratic steps of 0.15 and 0.5 M NaCl, respectively, in 130 mM NaAc pH 4.5 (Figure 1). Fractions were analyzed by SDS-PAGE and those containing the prominent 7 kDa band were pooled and applied to a Superdex 75 preparative grade (pg) size-exclusion chromatography (SEC) column equilibrated with 20 mM NaPO4, 0.15 M NaCl, 0.02% NaN3 pH 7.4. Elution was performed with equilibration buffer (Figure 2) and fractions containing the prominent 7 kDa band were pooled.

[0123] A biospecific affinity adsorption step was applied to specifically remove residual amounts of Pru p 3, which has a similar size and isoelectric point as Pru p 7. For this purpose, a proprietary monoclonal antibody against Pru p 3 was coupled to an NHS-activated Sepharose HP column. The SEC pool was purified by HPLC using 20 mM NaP i The eluate was applied to an anti-Pru p 3 affinity column equilibrated with pH 7.4, 150 mM NaCl, 0.02% NaN3. After elution with the equilibration buffer (Figure 3), the unbound material was collected and applied to a Source 15 RPC reversed-phase chromatography (RPC) column equilibrated with 0.1% TFA (Figure 4a). Bound protein was eluted with a linear gradient of 0–55% acetonitrile. Fractions were analyzed by SDS-PAGE (Figure 4b) and fractions containing the pure 7 kDa band were pooled as shown in Figure 4a and desalted on a Sephadex G25 column to 20 mM MOPS, 0.15 M NaCl pH 7.6.

[0124] Mass spectrometry (MS / MS) of nPru p 7 The pool of native Pru p 7 was analyzed by MS / MS analysis on an Orbitrap Fusion Tribrid instrument (Thermo Fisher Scientific, CA, USA) after reduction, alkylation, and enzymatic cleavage with either trypsin or chymotrypsin. Data analysis was performed on a combination of MS spectra obtained from these digestions. Data was analyzed against taxonomic ID 33090 in the Green Plant Database, confirming that the purified protein was Pru p 7 (SEQ ID NO: 1). No traces of Pru p 3 or other peach proteins were detected in the preparation.

[0125] In conclusion, Example 1 describes the purification of native Pru p 7 and the confirmation of its identity by MS / MS. This preparation was subsequently used to generate polyclonal rabbit antibodies against Pru p 7.

[0126] Example 2: Expression and purification of recombinant Pru p 7 A plasmid DNA construct containing a synthetic gene encoding Pru p 7 was prepared and transformed into the yeast Pichia pastoris strain X-33. The transformed strain was grown and induced to produce recombinant Pru p 7 in a 3 liter bioreactor (Belach Bioteknik, Skogás, Sweden). The medium was harvested by centrifugation and the supernatant was collected. After adjusting the pH to 4.5 with HAc and filtering through a Whatman GF / F glass microfiber filter, the supernatant was applied to an SP Sepharose FF column equilibrated with 50 mM NaAc pH 4.5. The recombinant protein was eluted with a linear 0-1 M NaCl gradient in the same buffer (Figure 5). Fractions containing rPru p 7 were collected and further purified by SEC on a Superdex 75 pg column in 50 mM NaAc pH 4.5, 150 mM NaCl (Figure 6a). Fractions containing rPru p 7 were pooled and yielded 0.72 mg of rPru p 7. -1 mL cm -1Concentrations were determined by absorbance at 280 nm using a calculated extinction coefficient of . Purity and identity of allergen preparations were verified by SDS-PAGE (Figure 6b) and mass spectrometry. An experimental ImmunoCAP test (Thermo Fisher Scientific, Uppsala, Sweden) was prepared as previously described

[42] and immunological activity was assessed using serum samples from relevant patients.

[0127] In conclusion, Example 2 describes the expression of rPru p 7 in Pichia pastoris and the purification of the recombinant protein. Recombinant Pru p 7 can be used to characterize the polyclonal rabbit antibodies raised against nPru p 7 and to study the IgE reactivity against Pru p 7 in relevant patient sera.

[0128] Example 3: Generation and use of polyclonal IgG antibodies against Pru p 7 Purified nPru p 7, prepared as described in Example 1, was used to generate polyclonal rabbit antibodies against Pru p 7. Rabbits were immunized with nPru p 7 according to a protocol involving four booster injections of antigen. Prior to immunization, pre-immune serum samples were taken from rabbits and used as controls in subsequent experiments. All procedures were performed at Agrisera AB (Vannas, Sweden) under local ethical approval.

[0129] The resulting anti-Pru p 7 antiserum was tested at a series of dilutions against both rPru p 7 immobilized on an ImmunoCAP solid phase and Cupressus sempervirens pollen extract. The antiserum showed stronger IgG binding to immobilized rPru p 7 compared to the previous serum, even at the highest dilution (1:8000) (Figure 7a), confirming the presence of Pru p 7-reactive IgG. Furthermore, the serum showed binding to C. sempervirens pollen extract (Figure 7b), suggesting the presence of a hitherto unknown protein that cross-reacts with Pru p 7. Thus, as shown in the following examples, the anti-Pru p 7 antiserum can be used as a probe to track down and purify this potential Cupressaceae pollen homologue of Pru p 7.

[0130] Example 4: Purification of novel Pru p 7-related C. sempervirens pollen allergens In Example 3, polyclonal rabbit IgG antibodies raised against Pru p 7 were shown to bind to immobilized protein extracts of C. sempervirens pollen. The same antibodies could be used to identify, purify, and characterize C. sempervirens pollen proteins that cross-react with Pru p 7.

[0131] In other words, C. sempervirens pollen (Allergon, Valinge, Sweden) was extracted with 50 mM NaAc, 1 M NaCl pH 4.5 at 4 °C for 72 h with stirring, clarified by centrifugation, filtered through Whatman GF / F glass microfiber filters, and desalted on a Sephadex G25 column equilibrated with 50 mM NaAc pH 4.5 (Figure 8). Protein-containing fractions eluting at the void volume were pooled and loaded onto a SP Sepharose FF column equilibrated with 50 mM NaAc pH 4.5. Elution was performed with a linear gradient from 0 to 1 M NaCl in the same buffer (Figure 9a). Nine selected fractions were immobilized on ImmunoCAP solid phase, assayed for anti-Pru p 7 IgG binding activity (Figure 9b) and analyzed by SDS-PAGE (Figure 9c). Fractions 7-9, which showed the highest binding of anti-Pru p 7 IgG and contained a prominent 7 kDa protein band, were pooled and concentrated on a SP Sepharose HP column, as shown in Figure 9a. The concentrated pool was further purified by SEC on a Superdex 30 pg column equilibrated with 20 mM NaAc pH 4.5, 250 mM NaCl. Elution was performed with the same buffer (Figure 10a). Eight selected fractions were immobilized on ImmunoCAP solid phase and tested for anti-Pru p 7 IgG binding activity as described above (Figure 10b) and analyzed by SDS-PAGE (Figure 10c). The highest binding of anti-Pru p 7 IgG was seen in fractions 3-5, which showed a single clear band at 7 kDa. Thus, fractions 3-5 were pooled as shown in Figure 10a, and this extensively purified Pru p 7-related C. sempervirens pollen protein was analyzed biochemically and immunologically as described below. The purified C. sempervirens protein showed an apparent molecular weight similar to that of Pru p 7 (FIG. 10d).

[0132] In conclusion, Example 4 describes how a novel C. sempervirens pollen protein, hereafter referred to as Cup s GRP, was purified using a series of chromatographic steps and the anti-Pru p 7 IgG antibody described in Example 3.

[0133] Example 5: Elucidation of the amino acid sequence of Cup s GRP To establish the identity and primary structure of the 7 kDa C. sempervirens pollen protein purified in Example 4, it was analyzed by MS / MS on an Orbitrap Fusion Tribrid instrument. Prior to MS analysis, the protein was reduced with DTT, alkylated with acrylamide, and enzymatically cleaved with either trypsin, chymotrypsin, or Lys-C. MS data analysis was performed on a combination of spectra obtained from three digests of the 7 kDa protein.

[0134] The NCBI protein database records did not provide a confirmatory perfect sequence match with the MS data. Therefore, a search was performed against hypothetical translations of nucleotide sequences present in the Cupressaceae EST (expressed sequence tag) database. The closest match in this database was record BY878079 (SEQ ID NO:2), a cDNA sequence from the male cone of Cryptomeria japonica (Figure 11a). This EST sequence contained an interrupted open reading frame (nucleotide positions 44-397) that translated into two hypothetical amino acid sequences (Figure 11b) separated by a stop codon at positions 302-304. Four peptides identified by MS / MS matched perfectly with the hypothetical amino acid sequence of BY878079, two on either side of the stop codon, as shown in Figure 11b. This observation raised the possibility that the stop codon at positions 302-304 was the result of a sequencing error.

[0135] In support of this notion, alignment between the interrupted BY878079-derived sequence and the amino acid sequence of Pru p 7 showed homology stretching across the stop codon at positions 302-304 (not shown). Indeed, when the A in the TGA stop codon was changed to either a T or a C, encoding a cysteine ​​residue instead, there was a perfect match with Pru p 7 at the corresponding position. After introducing such modifications in BY878079 (SEQ ID NO: 3), improved overall agreement of the MS / MS data was obtained, indicating that the purified Cup s GRP protein indeed had a cysteine ​​at the position corresponding to residue 87 of the hypothetical amino acid sequence derived from the modified BY878079 (FIG. 11b).

[0136] Using PEAKS Studio software (Bioinformatics Solutions Inc., Ontario, Canada) for analysis of the obtained MS / MS spectra, the complete 63-residue amino acid sequence of Cup s GRP (Figure 11c, SEQ ID NO: 4) could be determined in four iterative steps. The Cup s GRP sequence differed from the modified BY878079-derived sequence at four additional positions, as shown in Figure 11c. MS / MS analysis showed complete coverage of this amino acid sequence, corresponding to residues 55-117 of the sequence encoded by the modified BY878079 record. Examples of identified peptides that are part of this sequence are shown in Table 2a.

[0137] Furthermore, reanalysis of the MS / MS data using the newly determined Cup s GRP sequence as the target sequence revealed the presence of polymorphisms at two positions in the Cup s GRP sequence: position 18 (Ala / Leu) and position 52 (Asn / His) (Figure 11c, Table 2b). The originally determined Cup s GRP sequence containing Ala at position 18 and Asn at position 52 is referred to below as Cup s GRPa, and the sequence containing both alternative amino acids, i.e. Leu at position 18 and His at position 52, is referred to as Cup s GRPb (SEQ ID NO: 5). In addition to Cup s GRPa and Cup s GRPb, the existence of two other isoforms containing either one or the other of the two alternative amino acids is possible.

[0138] The amino acid sequence encoded by EST record BY878079 contained a predicted 24-residue signal peptide (underlined sequence in FIG. 11b). In addition, there was a 30 amino acid stretch between the signal peptide identified by MS / MS and the sequence matching Cup s GRP peptide 1 (Pep 1 in FIG. 11b) for which no matching Cup s GRP peptide was identified.

[0139] Nevertheless, to determine whether purified Cup s GRP contains such an N-terminal peptide, the protein was subjected to N-terminal sequencing by Edman degradation as described in

[43] . The first four amino acid residues of the protein were identified as Ala-Gln-Ile-Asp, which exactly matched the N-terminal portion of Cup s GRP peptide 1 identified by MS / MS. Thus, the precursor of Cup s GRP may contain a portion corresponding to residues 25-54 of the BY878079-derived sequence, which is truncated and no longer present in the mature Cup s GRP protein.

[0140] Evidence for the integrity of the Cup s GRP preparation and the newly determined amino acid sequence of the protein was obtained by MS analysis of the uncleaved protein, performed after reduction and alkylation of the sample, to determine its intact molecular weight. The analysis revealed a predominant peak at m / z=7682.43, corresponding to the molecular weight of 6828.98 Da of the unmodified protein with all cysteine ​​residues reduced. This is in perfect agreement with the monoisotopic molecular weight calculated for the Cup s GRPa sequence (SEQ ID NO: 4) with all cysteine ​​residues reduced.

[0141] N-terminal sequence and total mass MS analysis confirmed that the amino acid sequence obtained by MS / MS analysis covered the complete amino acid sequence of the 7 kDa protein purified from C. sempervirens pollen. Analysis of this amino acid sequence of Cup s GRP in the Pfam signature (http: / / pfam.xfam.org / ) confirmed that the protein belongs to the gibberellin-regulated protein family, also known as the GASA protein family. GRP sequences are highly conserved throughout the plant kingdom, with both Cup s GRPa and Cup s GRPb sequences showing 68% sequence identity with Pru p 7 (Figure 11d).

[0142] In conclusion, Example 5 describes how the amino acid sequence of Cup s GRP was determined by MS / MS and N-terminal sequencing. By MS analysis, the mass of the intact protein was determined and found to be in perfect agreement with the calculated theoretical mass. The 63 residue sequence was shown to have alternative amino acids at two positions, resulting in four possible isoforms of the protein in its native state.

[0143] Example 6: Purification and amino acid sequencing of Pru p 7-related proteins from Juniperus ashei and Cryptomeria japonica pollen The procedure developed for the purification of Cup s GRP described in Example 4 above was used to purify the corresponding protein from pollen of two other Cupressaceae species, Juniperus ashei and Cryptomeria japonica.

[0144] Pollen from J. ashei was extracted and subjected to the purification and monitoring procedures described. In the third purification step, SEC was used to separate proteins present in a concentrated pool of fractions from the previous cation exchange chromatography step. Three prominent peaks eluted from the SEC column (Figure 12a) and analysis of the individual fractions by SDS-PAGE (Figure 12b) revealed clearly distinct protein bands in each of the three peaks. The three peaks were pooled separately as shown in Figure 12a, bound to an ImmunoCAP solid phase, and analyzed for their ability to bind rabbit anti-Pru p 7 IgG antibody (Figure 12c).

[0145] Peak 2 was found to contain a predominant protein band at approximately 7 kDa and exhibited strong antibody binding activity. This protein preparation from J. ashei pollen, hereafter referred to as Jun a GRP, was analyzed biochemically and immunologically as described below.

[0146] Similarly, an extract of pollen from C. japonica was prepared, desalted, and subjected to cation exchange chromatography. Fractions showing antibody binding activity were pooled and applied to SEC (Figure 13a). This SEC chromatogram showed a more complex appearance than that obtained with J. ashei pollen extract. Selected fractions were analyzed for SDS-PAGE and binding of anti-Pru p 7 IgG. Analysis revealed a protein band of approximately 7 kDa in fractions 2 and 3 (Figure 13b, lanes 2 and 3), which also showed strong antibody binding activity (Figure 13c). Based on the results, fractions 2 and 3 were pooled, as indicated in brackets in Figure 13a. This protein preparation from C. japonica pollen, hereafter referred to as Cry j GRP, was biochemically and immunologically analyzed as described below.

[0147] The Jun a GRP preparation was analyzed by MS / MS analysis on an Orbitrap Fusion Tribrid instrument after sample preparation as described in Example 5. Again, the best database match for the obtained MS / MS spectrum was the EST record BY878079 (Figure 11a, SEQ ID NO: 2). Figure 14a shows a modified version of BY878079, in which the erroneous TGA stop codon at positions 302-304, as identified in Example 5, has been replaced by a cysteine ​​codon TGY (SEQ ID NO: 3), where Y represents C or T as defined by the IUPAC ambiguity code system

[44] . Figure 14b shows the amino acid sequence encoded by nucleotides 44-394 of the modified BY878079 (SEQ ID NO: 6), with the Jun a GRP peptide identified by MS / MS positioned below.

[0148] Using PEAKS Studio software for the analysis of the obtained MS / MS spectra, the complete amino acid sequence of Jun a GRP (Figure 14c, SEQ ID NO: 6) can be determined in four iterative steps. The Jun a GRP sequence differed from the corrected BY878079-derived sequence at five positions, as shown in Figure 14c. The MS / MS analysis showed complete coverage of this amino acid sequence, corresponding to residues 55-117 of the sequence encoded by the corrected BY878079 record. An example of an identified peptide representing this sequence is shown in Table 2c. No polymorphisms were detected in the analysis, and the sequence showed 67% identity with Pru p 7 (Figure 14d).

[0149] Evidence for the integrity of the Jun a GRP preparation and confirmation of the newly determined amino acid sequence was obtained by MS analysis of the uncleaved protein, performed after reduction of the sample with Tris(2-carboxyethyl)phosphine (TCEP). The analysis revealed a predominant peak at m / z=6829.04, corresponding to a molecular weight of 6828.03 Da, which is in perfect agreement with the monoisotopic mass calculated for the Jun a GRP sequence of SEQ ID NO:6, with all cysteine ​​residues reduced.

[0150] Cry j GRP preparations were analyzed by MS / MS on an Orbitrap Fusion Tribrid instrument after sample preparation as described in Example 5. The best database match for the obtained MS / MS spectra was the EST record BY900480, a cDNA sequence from the male cone of C. japonica (Figure 15a, SEQ ID NO: 7). In Figure 15b, the translated amino acid sequence of the open reading frame spanning nucleotide positions 15-365 of BY900480 is shown, with the Cry j GRP peptides identified by MS / MS positioned underneath. A list of selected Cry j GRP peptides identified by MS / MS, representing the entire protein, is shown in Table 2d. The complete amino acid sequence of Cry j GRP is shown in Figure 15c, SEQ ID NO: 8. No polymorphisms were detected in the analysis, and the sequence showed 68% identity with Pru p 7 (Figure 15d).

[0151] As with Cup s GRP and Jun a GRP, Cry j GRP lacked the first 54 residues of the amino acid sequence encoded by the closest matching database record. We conclude that, again, the first 24 residues contain the predicted signal peptide, and the following 30 residues represent a propeptide that is cleaved during protein maturation.

[0152] Evidence for the integrity of the Cry j GRP preparation and confirmation of the newly determined amino acid sequence was obtained by MS analysis of the uncleaved protein, performed after reduction of the sample with TCEP. The analysis revealed a large peak at m / z=6895.96, corresponding to a molecular weight of 6894.95 Da, which is in perfect agreement with the monoisotopic molecular weight mass calculated for the Cry j GRP sequence of SEQ ID NO:8 with all cysteine ​​residues reduced.

[0153] The three Cupressaceae pollen-derived GRP sequences, Cup s GRP, Jun a GRP, and Cry j GRP, share 90-98% sequence identity (Figures 16a-b) and have the same electrophoretic mobility in SDS-PAGE (Figure 16c).

[0154] In conclusion, Example 6 describes the purification, amino acid sequencing, and mass determination of the Pru p 7-related pollen proteins Jun a GRP and Cry j GRP from J. ashei and C. japonica, respectively.

[0155] Example 7: Cloning and purification of two recombinant Cup s GRP isoforms Synthetic genes designed to encode the amino acid sequences of Cup s GRPa and Cup s GRPb from Example 5 were cloned into the expression vector pPICZα A and transformed into Pichia pastoris strain X-33. The two recombinant proteins were expressed and purified using the same procedure as described for rPru p 7 in Example 2. MS / MS analysis confirmed the identity and integrity of the purified recombinant proteins. Comparison of the two recombinant isoforms of Cup s GRP, nCup s GRP, and rPru p 7 by SDS-PAGE showed an apparent molecular weight of 7 kDa and nearly identical electrophoretic appearance of the four protein preparations ( FIG. 17 ).

[0156] In conclusion, Example 7 describes the cloning and purification of two recombinant isoforms of Cup s GRP, which represent two of the amino acid sequence variants determined in Example 5.

[0157] Example 8: IgE-binding activity of native and recombinant Cup s GRP compared to rPru p 7 IgE antibody binding to purified nCup s GRP in sera from 44 peach-allergic subjects was analyzed by ImmunoCAP and compared to rPru p 7 (Figure 18). Of the 44 sera tested, 43 (98%) had detectable IgE responses (>= 0.1 kU) to nCup s GRP and 38 (86%) to rPru p 7. A / L). Five of six sera that tested negative to rPru p 7 showed positive IgE responses to nCup s GRP. The levels of IgE binding to nCup s GRP and rPru p 7 were significantly correlated (r=0.68), with the median binding being approximately two-fold higher than nCup s GRP. The analysis showed that Cup s GRP and Pru p 7 are immunologically related, but also that Pru p 7 possesses incomplete epitope presentation compared to Cup s GRP.

[0158] To evaluate the immunological activity and authenticity of the two recombinant Cup s GRP proteins produced, a comparison of IgE binding activity with nCup s GRP was performed in ImmunoCAP using sera from 19 peach-allergic subjects. The data shown in Figures 19a and 19b revealed essentially equivalent IgE binding activity (r=0.98 and r=0.99, respectively) of both rCup s GRPa (SEQ ID NO: 3) and rCup s GRPb (SEQ ID NO: 4) compared to nCup s GRP, with slightly higher IgE binding to rCup s GRPb than to rCup s GRPa. The results provide evidence of both the structural and immunological authenticity of the recombinant Cup s GRP proteins.

[0159] In conclusion, Example 8 confirms the immunological association between the peach allergen Pru p 7 and the C. sempervirens pollen protein Cup s GRP, first established by rabbit IgG antibodies, also with respect to recognition by human IgE antibodies. Secondly, the higher IgE levels bound to Cup s GRP than to Pru p 7 suggest that Cup s GRP may act as a primary sensitizer and induce IgE antibodies that cross-react with Pru p 7.

[0160] Example 9: Cross-reactivity between Pru p 7 and Cup s GRP To further characterize the immunological association between Pru p 7 and Cup s GRP, an IgE competition experiment was performed. Four Pru ​​p 7-reactive human sera were combined with nCup s GRP or rCup s GRPb individually at a final concentration of 20 μg / mL, or with the same volume ratio of dilution buffer alone, which served as a negative control. After 2 hours of incubation at room temperature to allow antibody / antigen complex formation, all samples were tested for IgE binding to Pru p 7 by ImmunoCAP. The level of inhibition of IgE binding to Pru p 7 by nCup s GRP and rCup s GRPb was calculated as a percentage of the dilution buffer control.

[0161] The experimental results are shown in Figure 20. In three of the four sera tested, both nCup s GRP and rCup s GRPb essentially completely inhibited IgE binding to rPru p 7. Also, in the fourth serum, IgE binding to rPru p 7 was completely defeated by nCup s GRP, whereas rCup s GRPb caused about 80% inhibition. In a separate control experiment, it was confirmed that nCup s GRP exerted no inhibitory effect on IgE binding to the unrelated birch pollen allergen Bet v 1, confirming the specificity of its effect on IgE binding to Pru p 7.

[0162] In conclusion, the IgE competition experiments indicate that the correlation in IgE binding to Pru p 7 and Cup s GRP is indeed caused by antibody recognition of an epitope structure common to the two proteins and not by covariation for other reasons.

[0163] Example 10: Immunological similarity between Cup s GRP, Jun a GRP, and Cry j GRP The degree of immunological similarity between the three native Cupressaceae pollen GRPs identified and purified in this study was assessed in a comparative IgE binding analysis. Each tree allergen was coupled to the ImmunoCAP solid phase and the assay was used to measure IgE antibody binding in the serum of 18 peach-allergic controls. A comparison is shown in Figures 21a-c. The levels of IgE binding with nCup s GRP and nJun a GRP (Figure 21a) were found to be highly correlated (r=0.98) with a slightly higher propensity for binding with nCup s GRP (median level ratio 1.12). nCup a GRP and nCry j GRP (Figure 21b) also showed a strong correlation with IgE binding (r=0.84), albeit with slightly higher binding with nCup s GRP (median level ratio 1.46), which may reflect a lack of primary sensitization to C. japonica pollen in the subjects whose serum was used in the analysis. Comparison of nJun a GRP and nCry j GRP (FIG. 21c) showed a similar correlation in IgE binding (r=0.87), again with slightly lower binding to nCry j GRP (median level ratio 1.28).

[0164] This example shows that four proteins (>90% sequence identity) from the GRP protein family have very similar IgE reactivity. This supports the observations made for other small allergen proteins of high sequence identity, where IgE reactivity remains essentially the same despite small variations in amino acid sequence. See also Example 12, which shows that IgE reactivity due to cross-reactivity is also very similar between closely related proteins within the same protein family.

[0165] Example 11: Prevalence of sensitization to Cup s GRP among subjects with cypress pollen allergy 88 subjects sensitized to cypress pollen (t23>0.1kU AIgE antibody binding to purified nCup s GRP among sera from 100 subjects (100 / L) was analyzed by ImmunoCAP (Figure 22). Of these sera, 28 (32%) had detectable IgE responses (>0.1 kU) to nCup s GRP. A In 13 of the sera (15%), we observed similar levels of IgE with nCup s GRP and cypress pollen extract, indicating a predominant role for Cup s GRP in cypress pollen sensitization of subjects in this subset.

[0166] Analysis suggests that approximately one-third of cypress pollen-sensitized subjects have a sensitization profile that confers a risk of allergic reaction to foods containing proteins homologous to cupressaceae pollen GRPs. Such individuals can be identified using an IgE test that includes a suitable representative cupressaceae pollen GRP.

[0167] More specifically, molecular analysis of hay fever patients unselected for peach allergy showed that only one third of these individuals had detectable IgE to Cup s GRP, while the majority of two thirds lacked sensitization to this allergen. This finding reveals that Cup s GRP is a minor allergen in cypress pollen and suggests that an identifiable subgroup of cypress pollen-sensitized patients is at risk for allergic reactions to peach or other GRP-containing foods. Given the substantial absolute numbers constituting this subgroup in areas of high cypress pollen exposure and the potential severity of GRP-mediated food allergic reactions, identifying those with GRP sensitization would be a valuable step in risk reduction in the management of this patient group. To this end, the generation of fully immunoreactive recombinant Cup s GRP, suitable as a reagent for in vitro diagnostic applications, as described in Example 7, is the first important step.

[0168] Example 12: Analysis of IgE reactivity of a closely related protein from the same protein family - profilin To demonstrate the compatibility of similar allergens, eight different profilin proteins from different allergen origins were compared. Recombinant profilins from birch (rBet v 2), hazelnut (Cor a 2), apple (Mal d 4), cherry (Pru av 4), pear (Pyr c 4), celery (Api g 4), carrot (Dau c 4), and timothy grass (Phl p 12) were immobilized on immunoCAP and tested using several sera. Comparison of IgE reactivity between each pair of proteins showed a strong correlation and very similar IgE binding activity of all proteins tested for the majority of the sera tested (Figure 23a).

[0169] The sequences of these proteins were aligned using the Emboss needle program

[45] (Figure 23b). The sequence identities ranged from 74% to 93% between these proteins.

[0170] When the sequence data are analyzed by structure prediction programs such as Phyre2

[46] , it can be concluded that all eight of these sequences match a folding structure close to that experimentally determined for profilin (data not shown).

[0171] The IgE data are in good agreement with those of Scheurer et al.

[47] , who compared four of these profilins. In that study, Bet v 2, Pru av 4, Pyr c 4, and Api g 4 were compared and it was concluded that these proteins show almost identical allergenic properties in cell-mediated release tests. The pairwise sequence identity of these four proteins varied between 76 and 86%. A similar conclusion and further evidence of high cross-reactivity between the profilins was presented in a study by Villalta et al.

[48] .

[0172] In conclusion, this example shows that IgE reactivity due to cross-reactivity is very similar between closely related proteins in the same protein family. In this study, the proteins were soluble and folded proteins of small size, with a pairwise sequence identity of about 80%. Although all the above studies were performed with naturally occurring protein variants, artificial variants of these proteins with high sequence identity with certain profilins would also show very similar IgE reactivity if the variants are provided in soluble folded proteins. Still, artificial variants of soluble and folded profilins can be designed by a limited number of amino acid substitutions at positions where the amino acids are not systematically conserved. If such substitutions are made with amino acids occurring in other profilins at any such position, this will increase the possibility of producing soluble folded proteins.

[0173] Example 13: Analysis of experimentally determined GRP sequences from pollen of different Cupressaceae species The four sequences that were assigned similar IgE antibody binding reactivity were aligned (Figure 24). From these four sequences, a Cupressaceae pollen GRP consensus sequence can be constructed in which all non-conserved amino acids are marked with X.

[0174] Additionally, a BLAST search was performed using this consensus sequence to identify all known sequences with homology to this consensus sequence. Notably, no known sequences exhibit greater than 70% (44 / 63) amino acid identity to this Cupressaceae pollen GRP consensus sequence, indicating that the sequences from Cupressaceae pollen identified herein are relatively distant in phylogeny from GRP proteins present in foods, such as Pru p 7.

[0175] A multiple sequence alignment was performed using a selection of 37 recorded sequences with sequence identity of more than 59% (37 / 63) with the consensus sequence. From this multiple sequence alignment (Figure 25), generated using the clustal omega program, 22 highly conserved amino acids were identified that were identical in all analyzed sequences, as shown in row C of Figure 26. Amino acid exchanges at these positions may result in structural changes that may affect the IgE-binding ability of the protein. In addition, 20 amino acids are identical between Pru p 7 and the phylogenetically more distant Cupressaceae pollen consensus sequence, see row B of Figure 26. Amino acid exchanges at these positions would have a high probability of inducing structural changes that may affect the IgE-binding ability of the protein. Finally, there are 14 amino acid residues that differ between the Cupressaceae pollen consensus sequence and Pru p 7, indicated by Z in row A of Figure 26. Amino acid substitutions at any one or more of these 14 amino acid positions Z to amino acid residues occurring in phylogenetically related proteins, as listed in Table 3, are unlikely to disrupt the overall structure of the protein.

[0176] From these sequences, a Cupressaceae-Pru p 7 GRP consensus sequence (SEQ ID NO:52) was designed, with all amino acids that are either non-conserved among Cupressaceae pollen GRPs or non-conserved between Cupressaceae pollen and Pru p 7 GRP indicated with an X (Figure 26 and SEQ ID NO:52).

[0177] By examining the alignment shown in Figure 25, we were able to identify all amino acids used at systematically non-conserved positions in the Cupressaceae-Pru p 7 GRP consensus sequence (the 21 X positions in Figure 26). In Table 3, we list these systematically tested amino acids, including those experimentally determined from Cupressaceae pollen GRP sequences (Figure 24).

[0178] References 1.Matricardi,P.M.,et al.,EAACI Molecular Allergology User’s Guide.2016.p.1-401. 2.Akdis,C.A.,Allergy and hypersensitivity:mechanisms of allergic disease.Curr Opin Immunol,2006.18(6):p.718-26. 3.Wainstein,B.K.,et al.,Combining skin prick,immediate skin application and specific-IgE testing in the diagnosis of peanut allergy in children.Pediatr Allergy Immunol,2007.18(3):p.231-9. 4.Valenta,R.,et al.,The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy(CRD and CRIT).Clinical and Experimental Allergy,1999.29(7):p.896-904. 5.Asarnoj,A.,et al.,IgE to peanut allergen components:relation to peanut symptoms and pollen sensitization in 8-year-olds.Allergy,2010.65(9):p.1189-95. 6.Asarnoj,A.,et al.,Peanut component Ara h 8 sensitization and tolerance to peanut.J Allergy Clin Immunol,2012.130(2):p.468-72. 7.Matsuo,H.,et al.,Sensitivity and specificity of recombinant omega-5 gliadin-specific IgE measurement for the diagnosis of wheat-dependent exercise-induced anaphylaxis.Allergy,2008.63(2):p.233-6. 8.Nicolaou,N.,et al.,Allergy or tolerance in children sensitized to peanut:prevalence and differentiation using component-resolved diagnostics.J Allergy Clin Immunol,2010.125(1):p.191-7 e1-13. 9.Codreanu,F.,et al.,A novel immunoassay using recombinant allergens simplifies peanut allergy diagnosis.Int Arch Allergy Immunol,2011.154(3):p.216-26. 10.Ebisawa,M.,et al.,Measurement of Ara h 1-,2-,and 3-specific IgE antibodies is useful in diagnosis of peanut allergy in Japanese children.Pediatr Allergy Immunol,2012.23(6):p.573-581. 11.Masthoff,L.J.,et al.,Sensitization to Cor a 9 and Cor a 14 is highly specific for a hazelnut allergy with objective symptoms in Dutch children and adults.J Allergy Clin Immunol,2013.132(2):p.393-9. 12.Savvatianos,S.,et al.,Sensitization to cashew nut 2S albumin,Ana o 3,is highly predictive of cashew and pistachio allergy in Greek children.J Allergy Clin Immunol,2015.136(1):p.192-4. 13.Lange,L.,et al.,Ana o 3-specific IgE is a good predictor for clinically relevant cashew allergy in children.Allergy,2017.72(4):p.598-603. 14.Stumvoll,S.,et al.,Identification of cross-reactive and genuine Parietaria judaica pollen allergens.Journal of Allergy and Clinical Immunology,2003.111(5):p.974-979. 15.Jutel,M.,et al.,Allergen-specific immunotherapy with recombinant grass pollen allergens.J Allergy Clin Immunol,2005.116(3):p.608-13. 16.Cromwell,O.,et al.,Strategies for recombinant allergen vaccines and fruitful results from first clinical studies.Immunol Allergy Clin North Am,2006.26(2):p.261-81,vii. 17.Nony,E.,et al.,Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.Allergy,2015.70(7):p.795-804. 18.Gronlund,H.,et al.,The Major Cat Allergen,Fel d 1,in Diagnosis and Therapy.Int Arch Allergy Immunol,2009.151(4):p.265-274. 19.Akdis,M.and C.A.Akdis,Mechanisms of allergen-specific immunotherapy.J Allergy Clin Immunol,2007.119(4):p.780-91. 20.Uermosi,C.,et al.,Mechanisms of allergen-specific desensitization.J Allergy Clin Immunol,2010.126(2):p.375-83. 21.Uermosi,C.,et al.,IgG-mediated down-regulation of IgE bound to mast cells:a potential novel mechanism of allergen-specific desensitization.Allergy,2014.69(3):p.338-47. 22.Pablos,I.,et al.,Pollen Allergens for Molecular Diagnosis.Curr Allergy Asthma Rep,2016.16(4):p.31. 23.Asam,C.,et al.,Tree pollen allergens-an update from a molecular perspective.Allergy,2015.70(10):p.1201-11. 24.Charpin,D.,et al.,Cypress Pollinosis:from Tree to Clinic.Clin Rev Allergy Immunol,2019.56(2):p.174-95. 25.Scala,E.,et al.,Cross-sectional survey on immunoglobulin E reactivity in 23,077 subjects using an allergenic molecule-based microarray detection system.Clin Exp Allergy,2010.40(6):p.911-21. 26.Aceituno,E.,et al.,Molecular cloning of major allergen from Cupressus arizonica pollen:Cup a 1.Clinical and Experimental Allergy,2000.30(12):p.1750-1758. 27.Cortegano,I.,et al.,Cloning and expression of a major allergen from Cupressus arizonica pollen,Cup a 3,a PR-5 protein expressed under polluted environment.Allergy,2004.59(5):p.485-490. 28.Pico de Coana,Y.,et al.,Molecular cloning and characterization of Cup a 4,a new allergen from Cupressus arizonica.Biochem Biophys Res Commun,2010.401(3):p.451-7. 29.Mattsson,L.,et al.,Molecular and immunological characterization of Can f 4:a dog dander allergen cross-reactive with a 23 kDa odorant-binding protein in cow dander.Clin Exp Allergy,2010.40(8):p.1276-87. 30.Rashid,R.S.,et al.,Pollen-food syndrome is related to Bet v 1 / PR-10 protein sensitisation,but not all patients have spring rhinitis.Allergy,2011.66(10):p.1391-2. 31.Worm,M.,et al.,Food allergies resulting from immunological cross-reactivity with inhalant allergens:Guidelines from the German Society for Allergology and Clinical Immunology(DGAKI),the German Dermatology Society(DDG),the Association of German Allergologists(AeDA)and the Society for Pediatric Allergology and Environmental Medicine(GPA).Allergo J Int,2014.23(1):p.1-16. 32.Rosace,D.,et al.,Profilin-mediated food-induced allergic reactions are associated with oral epithelial remodeling.J Allergy Clin Immunol,2019.143(2):p.681-690 e1. 33.Hugues,B.,A.Didierlaurent,and D.Charpin,Cross-reactivity between cypress pollen and peach:a report of seven cases.Allergy,2006.61(10):p.1241-3. 34.Tuppo,L.,et al.,Peamaclein - A new peach allergenic protein:similarities,differences and misleading features compared to Pru p 3.Clin Exp Allergy,2013.43(1):p.128-40. 35.Inomata,N.,et al.,Identification of peamaclein as a marker allergen related to systemic reactions in peach allergy.Ann Allergy Asthma Immunol,2014.112(2):p.175-177 e3. 36.Klingebiel,C.,et al.,Pru p 7 sensitisation is a predominant cause of severe,cypress pollen-associated peach allergy.Clin Exp Allergy,2019.49(4):p.526-36. 37.Senechal,H.,et al.,A new allergen family involved in pollen food-associated syndrome:Snakin / gibberellin-regulated proteins.J Allergy Clin Immunol,2018.141(1):p.411-414 e4. 38.Altschul,S.F.,et al.,Basic local alignment search tool.J Mol Biol,1990.215(3):p.403-10. 39.Altschul,S.F.,et al.,Gapped BLAST and PSI-BLAST:a new generation of protein database search programs.Nucleic Acids Res,1997.25(17):p.3389-402. 40.Coligan,J.E.,et al.,Production of Recombinant Proteins,in Current Protocols in Protein Science.2016,John Wiley&Sons,Inc.p.5.1.1-5.26.21. 41.Valenta,R.and V.Niederberger,Recombinant allergens for immunotherapy.J Allergy Clin Immunol,2007.119(4):p.826-30. 42.Marknell DeWitt,Å.,et al.,Molecular and immunological characterization of a novel timothy grass(Phleum pratense)pollen allergen,Phl p 11.Clinical&Experimental Allergy,2002.32(9):p.1329-1340. 43.Mattsson,L.,et al.,Prostatic kallikrein:A new major dog allergen.J Allergy Clin Immunol,2009.123(2):p.362-8. 44.Johnson,A.D.,An extended IUPAC nomenclature code for polymorphic nucleic acids.Bioinformatics,2010.26(10):p.1386-9. 45.Madeira,F.,et al.,The EMBL-EBI search and sequence analysis tools APIs in 2019.Nucleic Acids Res,2019.in press. 46.Kelley,L.A.,et al.,The Phyre2 web portal for protein modeling,prediction and analysis.Nature Protocols,2015.10(6):p.845-58. 47.Scheurer,S.,et al.,Cross-reactivity within the profilin panallergen family investigated by comparison of recombinant profilins from pear(Pyr c 4),cherry(Pru av 4)and celery(Api g 4)with birch pollen profilin Bet v 2.J Chromatogr B Biomed Sci Appl,2001.756(1-2):p.315-25. 48.Villalta,D.and R.Asero,Sensitization to the pollen pan-allergen profilin.Is the detection of immunoglobulin E to multiple homologous proteins from different sources clinically useful?J Investig Allergol Clin Immunol,2010.20(7):p.591-5.

Claims

1. An isolated allergen protein consisting of the amino acid sequence of SEQ ID NO:4, or a variant of said isolated allergen protein consisting of an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:

4.

2. 2. The isolated allergen protein or its variant according to claim 1, which has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:

4.

3. The isolated allergen protein or variant thereof consists of the following amino acid sequence of SEQ ID NO: 52: wherein up to four of the X positions include any amino acid at each position as defined in Table 3 below; 2. The isolated allergen protein or variant thereof according to claim 1, wherein in the remaining positions X, the amino acids are identical to the amino acids in the corresponding positions of SEQ ID NO:

4.

4. The isolated allergen protein or variant thereof consists of the following amino acid sequence of SEQ ID NO:9: Up to four of the X positions of SEQ ID NO:9 have an amino acid selected from the following group of amino acids: X at position 2 is selected from any one of Q, H, A, E, S, D, T, L, or Y; X at position 18 is selected from any one of A, L, Y, I, V, F, M, or R; X at position 31 is selected from any one of K, E, D, Q, A, G, or S; X at position 34 is selected from any one of H, N, Q, or K; X at position 41 is selected from any one of A, Y, F, or S; X at position 46 is selected from any one of V, S, E, V, A, or Q; and / or X at position 52 is selected from any one of H, N, D, or E; In the remaining positions X, the amino acids are identical to the amino acids in the corresponding positions of SEQ ID NO:

4.

3. An isolated allergen protein or a variant thereof according to claim 1 or 2.

5. At up to four of said positions X, said amino acids are selected from the group of amino acids: X at position 2 is selected from any one of Q or H; X at position 18 is selected from any one of A or L; X at position 31 is selected from any one of K or E; X at position 34 is selected from any one of H or N; X at position 41 is selected from any one of A or Y; X at position 46 is selected from any one of V or S; and X at position 52 is selected from any one of H or N; 5. The isolated allergen protein or its variant according to claim 4.

6. 2. The isolated allergen protein or variant thereof of claim 1, wherein the isolated allergen protein or variant thereof consists of the amino acid sequence of SEQ ID NO:

4.

7. The isolated allergen protein or variant thereof of claim 1, wherein the isolated allergen protein or variant thereof consists of the amino acid sequence of SEQ ID NO:5 or has at least 93% sequence identity with the amino acid sequence of SEQ ID NO:

5.

8. The isolated allergen protein or variant thereof according to claim 1, wherein the isolated allergen protein or variant thereof consists of the amino acid sequence of SEQ ID NO:6 or consists of an amino acid sequence having at least 92% sequence identity with the amino acid sequence of SEQ ID NO:

6.

9. The isolated allergen protein or variant thereof according to claim 1, wherein the isolated allergen protein or variant thereof consists of the amino acid sequence of SEQ ID NO:8 or consists of an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO:

8.

10. 10. The isolated allergen protein or variant thereof according to any one of claims 1 to 9, wherein said isolated allergen protein or variant thereof is recombinantly produced.

11. An isolated nucleic acid molecule encoding the isolated allergen protein or a variant thereof according to any one of claims 1 to 10.

12. 12. The isolated nucleic acid molecule of claim 11, wherein the nucleic acid molecule has the nucleic acid sequence of SEQ ID NO:

10.

13. An expression vector comprising the isolated nucleic acid molecule of claim 12.

14. 14. An isolated host cell comprising the expression vector of claim 13.

15. 11. A method for producing an allergen composition, comprising the step of adding an isolated allergen protein or variant thereof according to any one of claims 1 to 10 to a composition comprising an allergen extract and / or at least one purified allergen component.

16. An allergen composition obtainable by the method according to claim 15.

17. Use of the isolated allergen protein or variant thereof according to any one of claims 1 to 10 for the in vitro diagnosis or assessment of type 1 allergy.

18. 18. The use according to claim 17, wherein the type 1 allergy is caused by pollen of Cupressaceae species.

19. 18. The use according to claim 17, wherein the type 1 allergy is food-related.

20. 20. The use according to claim 19, wherein the type 1 allergy is associated with fruit.

21. The use according to claim 17, wherein the type 1 allergy is associated with pollen foods.

22. 22. The use according to claim 21, wherein the type 1 allergy is associated with pollen-food associated syndrome (PFAS).

23. 1. A method for the in vitro diagnosis or assessment of type 1 allergy comprising: contacting an immunoglobulin-containing body fluid sample from a subject suspected of having type 1 allergy with an isolated allergen protein or variant thereof according to any one of claims 1 to 10; determining the presence in said sample of an antibody which specifically binds to said isolated allergen protein or variant thereof, The presence of antibodies in the sample that specifically bind to the isolated allergen protein or variant thereof provides information of type 1 allergy in the subject.

24. A kit for use in the method according to claim 23, comprising an isolated allergen protein or a variant thereof according to any one of claims 1 to 10, either soluble or immobilised on a solid support.

25. A pharmaceutical composition comprising the isolated allergen protein or variant thereof according to any one of claims 1 to 10, and a pharma- ceutically acceptable carrier and / or excipient.

Images